<!DOCTYPE html><html lang="en-GB"><head><meta charSet="utf-8"/><meta http-equiv="x-ua-compatible" content="ie=edge"/><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/><style data-href="/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css" id="gatsby-global-css">.page-header{margin:0 0 3rem}.page-header__pre-heading{font-size:1.125rem;line-height:1.5rem;display:block;margin:0}.page-header__heading{font-size:2.75rem;line-height:3.5rem;margin:0 0 .5rem}.page-header__lead{font-size:1.25rem;line-height:1.75rem;margin:0 0 .5rem}.page-header__cta{font-size:1rem;line-height:1.5rem;display:block;margin:0}@media print{.page-header__cta{display:none!important}}.breadcrumbs{font-size:1rem;line-height:1.5rem;list-style:none;margin:.5em 0 2em;max-width:100%;padding:0}@media print{.breadcrumbs{display:none!important}}.breadcrumbs__crumb{display:inline-block}.breadcrumbs__crumb:before{content:">";font-size:80%;margin:0 .25em}.breadcrumbs__crumb:first-child:before{display:none}.breadcrumbs a{color:#222;text-decoration:underline}.breadcrumbs a:hover{text-decoration:none}.breadcrumbs a:focus{color:#005ea5}.breadcrumbs a:active{color:#222}.OldIEMessage-module--container--2Z9pT{max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);margin:auto auto 1rem}.OldIEMessage-module--alert--3CB3M{background:#ffdfa4;border:1px solid #966f2f;margin:1rem auto 0;max-width:73.125rem;padding:1rem}.OldIEMessage-module--alert--3CB3M a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.OldIEMessage-module--alert--3CB3M a:visited{color:#4c2c92}.OldIEMessage-module--alert--3CB3M a:hover{color:#2e8aca}.OldIEMessage-module--alert--3CB3M a:focus{outline:.25rem solid #0092a6;color:#005ea5}.OldIEMessage-module--alert--3CB3M a:active{color:#222}.OldIEMessage-module--alert--3CB3M h2{margin-top:0}.OldIEMessage-module--alert--3CB3M h2,.OldIEMessage-module--alert--3CB3M p{max-width:600px}.OldIEMessage-module--lastP---CQws{margin-bottom:0}.CoronaMessage-module--wrapper--zRiaV{background:#ffeb3b;padding:.5rem 0}.CoronaMessage-module--wrapper--zRiaV p{margin-top:0}.CoronaMessage-module--wrapper--zRiaV a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.CoronaMessage-module--wrapper--zRiaV a:visited{color:#4c2c92}.CoronaMessage-module--wrapper--zRiaV a:hover{color:#2e8aca}.CoronaMessage-module--wrapper--zRiaV a:focus{outline:.25rem solid #0092a6;color:#005ea5}.CoronaMessage-module--wrapper--zRiaV a:active{color:#222}@media print{.CoronaMessage-module--wrapper--zRiaV{display:none}}.CoronaMessage-module--container--36Biz{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.CoronaMessage-module--container--36Biz>:last-child{margin-bottom:0}.SubNav-module--wrapper--yAXWY{background:#fff;color:#000;display:block}.SubNav-module--list--1K9bK{margin:0;padding:0}.SubNav-module--list--1K9bK li{list-style:none;margin:0}.SubNav-module--link--39i23{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222;display:block;font-weight:400;padding:.5rem 1rem .5rem 2rem;text-decoration:none}.SubNav-module--link--39i23:focus{color:#222;outline:.25rem solid #0092a6;outline-offset:-.5rem}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222}.SubNav-module--link--39i23:hover{background:#d6d6d6;color:#222;text-decoration:underline}.SubNav-module--imageLink--3xwIS{display:none}@media(min-width:56.25em){.SubNav-module--wrapper--yAXWY{border-bottom:.125rem solid #004650;bottom:0;height:3rem;left:0;position:absolute;width:100%}.SubNav-module--imageLink--3xwIS{display:inline-block}.SubNav-module--list--1K9bK{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);height:100%}.SubNav-module--list--1K9bK li{display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23{border:0;display:block;height:100%;padding:0 1rem}.SubNav-module--link--39i23[aria-current=page],.SubNav-module--link--39i23[aria-current=true]{background:transparent}.SubNav-module--link--39i23[aria-current=page]:after,.SubNav-module--link--39i23[aria-current=true]:after{display:none}.SubNav-module--link--39i23:before{content:"";display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border:0}}.SubNav-module--image--uq-a2{height:100%}.Nav-module--link--3JzDA .Nav-module--tooltip--1Uj-W{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Nav-module--link--3JzDA:focus-visible .Nav-module--tooltip--1Uj-W{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Nav-module--visuallyHidden--ORHqX{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Nav-module--wrapper--2_xng{display:none;position:relative}@media print{.Nav-module--wrapper--2_xng{display:none!important}}@media(min-width:56.25em){.Nav-module--wrapper--2_xng{display:block}}.Nav-module--wrapperExpanded--3RxQB{display:block}.Nav-module--nav--2aQpa abbr[title]{border-bottom:0;cursor:help;text-decoration:none}.Nav-module--myAccount--3lsif{border-top:1px solid #fff}@media(min-width:56.25em){.Nav-module--myAccount--3lsif{display:none}}.Nav-module--myAccountHeading--1A5_B{border:.25rem solid #004650;font-size:100%;margin:0;padding:.5rem 1rem}.Nav-module--menuWrapper--2fp8S{background:#004650;color:#fff;padding:.25rem 0}.Nav-module--menuList--264L-{list-style:none;margin:auto;padding:0}.Nav-module--menuList--264L->li{margin:0}a.Nav-module--link--3JzDA{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#fff;display:block;font-weight:400;padding:.5rem 1rem;text-decoration:none}a.Nav-module--link--3JzDA span{text-decoration:inherit}a.Nav-module--link--3JzDA:focus{color:#fff;outline:.25rem solid #fff;outline-offset:-.5rem;z-index:1}a.Nav-module--link--3JzDA:visited{color:#fff}a.Nav-module--link--3JzDA:active{background:#acadad;color:#222}a.Nav-module--link--3JzDA:hover{background:#d6d6d6;color:#222;text-decoration:underline}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{background:#fff;color:#222;font-weight:700}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-color:#0092a6;outline-offset:-.25rem}@media(min-width:56.25em){.Nav-module--wrapperWithSubLinks--3PUfX{padding-bottom:3rem}.Nav-module--menuList--264L-{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);display:-webkit-flex;display:flex;-webkit-flex-direction:row;flex-direction:row;-webkit-flex-wrap:nowrap;flex-wrap:nowrap;-webkit-justify-content:space-between;justify-content:space-between}.Nav-module--menuList--264L->li{-webkit-flex-grow:1;flex-grow:1}a.Nav-module--link--3JzDA{border-left-width:0;border-right-width:0;display:-webkit-flex;display:flex;-webkit-flex-direction:column;flex-direction:column;height:100%;-webkit-justify-content:center;justify-content:center;line-height:1.25;margin:0;padding:.5rem;position:relative;text-align:center}a.Nav-module--link--3JzDA:focus{outline-offset:-.25rem}a.Nav-module--link--3JzDA span{display:inline-block;vertical-align:middle;white-space:normal}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{margin:0 .25rem}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-offset:-.5rem}a.Nav-module--link--3JzDA[aria-current=page]:after,a.Nav-module--link--3JzDA[aria-current=true]:after{background:#fff;content:"";display:block;height:.25rem;left:0;position:absolute;top:100%;width:100%}a.Nav-module--link--3JzDA[aria-current=page]:hover:after,a.Nav-module--link--3JzDA[aria-current=true]:hover:after{background:#d6d6d6}}@media(min-width:56.25em)and (min-width:75em){a.Nav-module--link--3JzDA{padding:1rem}}.Autocomplete-module--ac--2PqiF .autocomplete__wrapper{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input{-webkit-appearance:none;border:1px solid #222;border-radius:0;box-sizing:border-box;margin-bottom:0;width:100%}.Autocomplete-module--ac--2PqiF .autocomplete__input{background-color:#e9e9e9!important;height:2.5rem!important;margin:0!important;max-width:100%!important;position:relative;z-index:101}.Autocomplete-module--ac--2PqiF .autocomplete__input:focus{outline:3px solid #0092a6;outline-offset:-3px;z-index:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-webkit-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-moz-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input:-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__hint{color:#bfc1c3;position:absolute}.Autocomplete-module--ac--2PqiF .autocomplete__input--default{padding:.5rem}.Autocomplete-module--ac--2PqiF .autocomplete__input--focused{outline:3px solid #0092a6;outline-offset:-3px}.Autocomplete-module--ac--2PqiF .autocomplete__input--show-all-values{padding:4px 34px 4px 4px;cursor:pointer}.Autocomplete-module--ac--2PqiF .autocomplete__dropdown-arrow-down{z-index:-1;display:inline-block;position:absolute;right:8px;width:24px;height:24px;top:10px}.Autocomplete-module--ac--2PqiF .autocomplete__menu{background-color:#fff;border:1px solid #d6d6d6;border-top:0;color:#34384b;margin:0;max-width:100%;padding:0;text-align:left;width:-webkit-calc(100vw - 2rem);width:calc(100vw - 2rem)}@media(min-width:37.5em){.Autocomplete-module--ac--2PqiF .autocomplete__menu{width:100%}}.Autocomplete-module--ac--2PqiF .autocomplete__menu--visible{display:block}.Autocomplete-module--ac--2PqiF .autocomplete__menu--hidden{display:none}.Autocomplete-module--ac--2PqiF .autocomplete__menu--overlay{box-shadow:0 .25rem 1rem .25rem rgba(0,0,0,.1);left:0;position:absolute;top:100%;z-index:100}.Autocomplete-module--ac--2PqiF .autocomplete__menu--inline{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option{border-left-width:0;border-bottom:1px solid #d6d6d6;border-right-width:0;border-top-width:1px;color:#005ea5;cursor:pointer;display:block;margin:0;position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option a{color:inherit;display:block;font-weight:400;padding:.5rem;text-decoration:none}.Autocomplete-module--ac--2PqiF .autocomplete__option mark{background:0;color:inherit;font-weight:700;padding:0}.Autocomplete-module--ac--2PqiF .autocomplete__option>*{pointer-events:none}.Autocomplete-module--ac--2PqiF .autocomplete__option:first-of-type{border-top-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option:last-of-type{border-bottom-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option--odd{background-color:#fafafa}.Autocomplete-module--ac--2PqiF .autocomplete__option--focused,.Autocomplete-module--ac--2PqiF .autocomplete__option:hover{background-color:#e9e9e9;color:#005ea5;outline:none;text-decoration:underline}.Autocomplete-module--ac--2PqiF .autocomplete__option--no-results{background-color:#fafafa;color:#646b6f;cursor:not-allowed}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input,.Autocomplete-module--ac--2PqiF .autocomplete__option{font-size:16px;line-height:1.25}.Search-module--search--2wNll{margin:0;padding-right:2.5rem;position:relative}.Search-module--label--1rrog{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute!important;width:1px}.Search-module--button--2FbnI{background:#393939;border:0;color:#fff;cursor:pointer;height:2.5rem;min-width:2.5rem;padding:0 .5rem;position:absolute;right:0;text-align:center;top:0;z-index:101}.Search-module--button--2FbnI:focus{outline:.25rem solid #0092a6}.Search-module--button--2FbnI .Search-module--icon--2JB42{font-size:150%;vertical-align:middle}.Account-module--account--1BtRh{position:relative}.Account-module--button--zZii1{background:#fff;border:1px solid #222;color:#222;cursor:pointer;display:inline-block;font-family:inherit;font-size:inherit;font-weight:400;height:2.5rem;line-height:2.5rem;padding:0 .5rem;text-decoration:none;vertical-align:middle;white-space:nowrap}.Account-module--button--zZii1:focus{outline:.25rem solid #0092a6}.Account-module--button--zZii1:visited{color:#222}.Account-module--button--zZii1:hover{border:1px solid #222}.Account-module--myAccount--3jTaq:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Account-module--myAccount--3jTaq[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Account-module--menu--3C46i{background:#fff;border:1px solid #393939;list-style:none;margin:.625rem 0 0;padding:0;position:absolute;right:0;top:100%;z-index:2}.Account-module--menu--3C46i:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i[aria-hidden=true]{display:none}.Account-module--menu--3C46i:before{border-bottom:.5rem solid #393939;border-left:.25rem solid transparent;border-right:.25rem solid transparent}.Account-module--menu--3C46i:after,.Account-module--menu--3C46i:before{bottom:100%;content:"";display:block;height:0;position:absolute;right:1rem;width:0}.Account-module--menu--3C46i:after{border-bottom:.4rem solid #fff;border-left:.2rem solid transparent;border-right:.2rem solid transparent;margin-right:1px}.Account-module--menu--3C46i li{border-top:1px solid #d6d6d6;list-style:none;margin:0}.Account-module--menu--3C46i a{color:#005ea5;display:block;padding:.5rem 1rem;text-decoration:none;white-space:nowrap}.Account-module--menu--3C46i a:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i a:hover{background:#e9e9e9;text-decoration:underline}.Header-module--header--3os44{background:#fff;border-bottom:.125rem solid #004650;box-sizing:border-box;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif}.Header-module--header--3os44 *,.Header-module--header--3os44 :after,.Header-module--header--3os44 :before{box-sizing:inherit;font-family:inherit}@media print{.Header-module--header--3os44{border-bottom:none}}.Header-module--container--1mfIr{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0 0}.Header-module--container--1mfIr:after{clear:both;content:"";display:table}.Header-module--home--1TCPb{color:#000;display:inline-block;float:left;height:1.875rem;margin-bottom:1rem}@media print{.Header-module--home--1TCPb:after{content:none!important}}.Header-module--home--1TCPb:focus{outline:.25rem solid #0092a6}.Header-module--home--1TCPb:visited{color:#000}.Header-module--home--1TCPb .Header-module--icon--4LSt5{height:100%;width:auto}.Header-module--wrapper--2e13D{display:-webkit-flex;display:flex;-webkit-flex-grow:1;flex-grow:1;float:right;-webkit-justify-content:space-between;justify-content:space-between;margin-bottom:1rem;width:50%}@media print{.Header-module--wrapper--2e13D{display:none!important}}.Header-module--wrapper--2e13D:after{clear:both;content:"";display:table}.Header-module--search--2nfnz{-webkit-flex-grow:1;flex-grow:1;float:left;margin-right:1rem;min-width:66.6666666667%}.Header-module--mobileMenuBtn--1LgyL{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:1px solid #222;float:right;font-family:inherit;font-size:110%;height:2.5rem;min-width:4.6875rem;white-space:nowrap}.Header-module--mobileMenuBtn--1LgyL:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Header-module--mobileMenuBtn--1LgyL[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Header-module--account--y72Q4{display:none}@media(max-width:56.24em){.Header-module--home--1TCPb{float:none}.Header-module--wrapper--2e13D{float:none;width:auto}}@media(min-width:56.25em){.Header-module--header--3os44{border-bottom:.25rem solid #fff}.Header-module--container--1mfIr{display:-webkit-flex;display:flex;-webkit-justify-content:space-between;justify-content:space-between}.Header-module--home--1TCPb{height:2.5rem;margin-right:2rem}.Header-module--wrapper--2e13D{-webkit-justify-content:flex-end;justify-content:flex-end}.Header-module--search--2nfnz{margin-right:2rem}.Header-module--mobileMenuBtn--1LgyL{display:none}.Header-module--account--y72Q4{display:block}}.SkipLinks-module--list--1WwLa{list-style:none;margin:0;padding:0}@media print{.SkipLinks-module--list--1WwLa{display:none!important}}.SkipLinks-module--list--1WwLa li{list-style:none;margin:0}.SkipLinks-module--link--hkZw8{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.SkipLinks-module--link--hkZw8:focus{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;left:.25rem;outline:3px solid #0092a6;overflow:visible;padding:.5rem 1rem;position:absolute;top:.25rem;white-space:nowrap;width:auto;z-index:1}.Social-module--wrapper--2nKsd{clear:left}.Social-module--list--E5R5J{list-style:none;margin:0;max-width:100%;padding:0}.Social-module--list--E5R5J li{margin:0 0 .25rem}.Social-module--list--E5R5J svg{margin:-.125rem .25rem 0 0;vertical-align:middle}@media(min-width:37.5em){.Social-module--list--E5R5J li{float:left;margin:0 1rem 0 0}}@media(min-width:56.25em){.Social-module--wrapper--2nKsd{clear:none}.Social-module--wrapper--2nKsd li{float:none;margin:0 0 .25rem}}.Legal-module--wrapper--3AYMO{font-size:.875rem;line-height:1.25rem;background:#393939;padding:1rem 0}.Legal-module--wrapper--3AYMO a{text-decoration:underline}.Legal-module--container--3TTBh{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.Legal-module--menu--1e1Iy{margin:0 0 1rem}@media print{.Legal-module--menu--1e1Iy{display:none!important}}.Legal-module--menu--1e1Iy ul{list-style:none;margin:0;max-width:100%;padding:0}.Legal-module--menu--1e1Iy li{margin:0}.Legal-module--menu--1e1Iy a{display:block}.Legal-module--copyright--34nsI{font-size:.875rem;line-height:1.25rem;margin:0}@media print{.Legal-module--copyright--34nsI{float:none!important;max-width:100%}}@media(min-width:37.5em){.Legal-module--menu--1e1Iy li{display:inline-block;margin-right:1rem}}@media(min-width:75em){.Legal-module--wrapper--3AYMO:after,.Legal-module--wrapper--3AYMO:before{content:" ";display:table}.Legal-module--wrapper--3AYMO:after{clear:both}.Legal-module--menu--1e1Iy{float:left;margin:0}.Legal-module--copyright--34nsI{float:right}}.Services-module--link--2y_1q .Services-module--tooltip--pg3nW{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Services-module--link--2y_1q:focus-visible .Services-module--tooltip--pg3nW{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Services-module--visuallyHidden--t9mfm{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Services-module--wrapper--2qOoE{margin:0 0 2rem}.Services-module--list--3SZQu{list-style:none;margin:0;padding:0}.Services-module--list--3SZQu li{margin:0 0 .25rem}@media(min-width:37.5em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;width:33.3333333333%}}@media(min-width:56.25em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;margin:0;width:25%}}.Pages-module--wrapper--30REl{margin:0 0 2rem}.Pages-module--list--vvSk4{list-style:none;margin:0;padding:0}.Pages-module--list--vvSk4 li{margin:0 0 .25rem}@media(min-width:25em){.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}@media(min-width:37.5em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 0 0 2rem;width:66.6666666667%}}@media(min-width:56.25em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 2rem;width:50%}.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}.Footer-module--link--CGIYk .Footer-module--tooltip--1zoJv{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Footer-module--link--CGIYk:focus-visible .Footer-module--tooltip--1zoJv{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Footer-module--visuallyHidden--3CCnP{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Footer-module--footer--2QrGZ{background:#222;box-sizing:border-box;color:#fff;contain-intrinsic-size:350px;content-visibility:auto;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;margin:2rem 0 0}.Footer-module--footer--2QrGZ a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.Footer-module--footer--2QrGZ a:visited{color:#fff}.Footer-module--footer--2QrGZ a:hover{color:#d6d6d6}.Footer-module--footer--2QrGZ a:focus{outline:.25rem solid #fff;color:#fff}.Footer-module--footer--2QrGZ a:active{color:#d6d6d6}.Footer-module--footer--2QrGZ *,.Footer-module--footer--2QrGZ :after,.Footer-module--footer--2QrGZ :before{box-sizing:inherit}.Footer-module--footer--2QrGZ a{font-weight:400}.Footer-module--container--1iuoB{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0}.Footer-module--container--1iuoB:after,.Footer-module--container--1iuoB:before{content:" ";display:table}.Footer-module--container--1iuoB:after{clear:both}@media print{.Footer-module--container--1iuoB{display:none!important}}.Footer-module--logo--3DGKv{display:block;height:0;margin:0 0 2rem;padding:0 0 29.0496453901px;position:relative;width:80px}.Footer-module--logo--3DGKv svg{display:block;height:100%!important;left:0;position:absolute;top:0;width:100%!important}@media(min-width:56.25em){.Footer-module--logo--3DGKv{margin-bottom:1rem}}.BackToTop-module--wrapper--2Z0EU{margin-top:3rem}@media print{.BackToTop-module--wrapper--2Z0EU{display:none}}.BackToTop-module--nav--1DPZ6{background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}.BackToTop-module--anchor--1Nia6{display:block;line-height:1rem;padding:1rem 0}.BackToTop-module--anchor--1Nia6:visited{color:#005ea5}.BackToTop-module--anchor--1Nia6 svg{-webkit-transition:all .25s ease;transition:all .25s ease}.BackToTop-module--anchor--1Nia6:hover{background:#f4f4f4}.BackToTop-module--anchor--1Nia6:hover svg{-webkit-transform:translateY(-.125rem);transform:translateY(-.125rem)}@supports((position:-webkit-sticky) or (position:sticky)){.BackToTop-module--wrapper--2Z0EU{bottom:0;left:0;margin:0;pointer-events:none;position:absolute;right:0;top:min(100vh,-webkit-calc(100% - 3rem));top:min(100vh,calc(100% - 3rem));width:100%;z-index:99}.BackToTop-module--nav--1DPZ6{position:-webkit-sticky;position:sticky;pointer-events:all;top:-webkit-calc(100vh - 3rem);top:calc(100vh - 3rem);background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-regular.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-regular.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:italic;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-italic.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-italic.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:700;src:local("Lato"),url(../../../../fonts/lato-v17-latin-700.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-700.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:900;src:local("Lato"),url(../../../../fonts/lato-v17-latin-900.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-900.woff) format("woff")}/*! normalize.css v8.0.1 | MIT License | github.com/necolas/normalize.css */html{line-height:1.15;-webkit-text-size-adjust:100%}body{margin:0}main{display:block}h1{font-size:2em;margin:.67em 0}hr{box-sizing:content-box;height:0;overflow:visible}pre{font-family:monospace,monospace;font-size:1em}a{background-color:transparent}abbr[title]{border-bottom:none;text-decoration:underline;-webkit-text-decoration:underline dotted;text-decoration:underline dotted}b,strong{font-weight:bolder}code,kbd,samp{font-family:monospace,monospace;font-size:1em}small{font-size:80%}sub,sup{font-size:75%;line-height:0;position:relative;vertical-align:baseline}sub{bottom:-.25em}sup{top:-.5em}img{border-style:none}button,input,optgroup,select,textarea{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=button],[type=reset],[type=submit],button{-webkit-appearance:button}[type=button]::-moz-focus-inner,[type=reset]::-moz-focus-inner,[type=submit]::-moz-focus-inner,button::-moz-focus-inner{border-style:none;padding:0}[type=button]:-moz-focusring,[type=reset]:-moz-focusring,[type=submit]:-moz-focusring,button:-moz-focusring{outline:1px dotted ButtonText}fieldset{padding:.35em .75em .625em}legend{box-sizing:border-box;color:inherit;display:table;max-width:100%;padding:0;white-space:normal}progress{vertical-align:baseline}textarea{overflow:auto}[type=checkbox],[type=radio]{box-sizing:border-box;padding:0}[type=number]::-webkit-inner-spin-button,[type=number]::-webkit-outer-spin-button{height:auto}[type=search]{-webkit-appearance:textfield;outline-offset:-2px}[type=search]::-webkit-search-decoration{-webkit-appearance:none}::-webkit-file-upload-button{-webkit-appearance:button;font:inherit}details{display:block}summary{display:list-item}[hidden],template{display:none}.show-print{display:none!important}@media print{.show-print{display:block!important}}@media print{.hide-print{display:none!important}}@media print{.remove-appended-print-link:after{content:none!important}}@media print{*{background:transparent!important;box-shadow:none!important;color:#000!important;text-shadow:none!important}a,a:visited{text-decoration:underline}}@media print{h1 a:after,h2 a:after,h3 a:after,h4 a:after,h5 a:after,h6 a:after{content:none!important}}@media print{a[href]:after{content:" (" attr(href) ")"}}@media print{abbr[title]:after{content:" (" attr(title) ")"}}@media print{.ir a:after,a[href^="#"]:after,a[href^="javascript:"]:after{content:""}}@media print{blockquote,pre{border:1px solid #999;page-break-inside:avoid}}@media print{thead{display:table-header-group}}@media print{img,tr{page-break-inside:avoid}}@media print{img{max-width:100%!important}}@media print{img:not([alt]),img[alt=""]{display:none!important}}@media print{@page{margin:.5cm}}@media print{h2,h3,p{orphans:3;widows:3}}@media print{h2,h3{page-break-after:avoid}}.clearfix:after,.clearfix:before{content:" ";display:table}.clearfix:after{clear:both}.container{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.container--full{max-width:100%;padding:0 2%;width:auto}html{box-sizing:border-box;font-size:.9375rem;overflow-x:hidden}html *,html :after,html :before{box-sizing:inherit}@media(min-width:56.25em){html{font-size:1.03125rem;font-size:-webkit-calc(.375rem + 1vw);font-size:calc(.375rem + 1vw)}}@media(min-width:75em){html{font-size:1.125rem}}body{background:#f4f4f4;color:#222;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;font-style:normal;line-height:1.5rem;overflow-x:hidden;text-rendering:optimizelegibility}img{max-width:100%}hr{background:0;border:0;border-top:.0625em solid #adadad;margin:2em 0;padding:0}.p,p{font-size:1rem;line-height:1.5rem;font-feature-settings:"kern","onum","liga"}.lead,.p,p{margin-bottom:1rem;margin-top:1rem;font-weight:400;max-width:66ch}.lead{font-size:1.25rem;line-height:1.75rem}code{background:#e9e9e9;border:1px solid #adadad;border-radius:.125em;color:#222;display:inline-block;font-family:Monaco,Menlo,Consolas,Courier New,monospace;margin:0 0 .125em;padding:0 .25em}pre code{background:transparent;border:0;margin:0}.mark,mark{background-color:#fff999;padding:0 .25em}.small,small{font-size:85%}.h6,h6{font-size:1rem}.h5,.h6,h5,h6{line-height:1.5rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h5,h5{font-size:1.125rem}.h4,h4{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h3,h3{font-size:1.75rem;line-height:2rem}.h2,.h3,h2,h3{margin-bottom:1rem;margin-top:2rem;clear:both;font-weight:700;max-width:66ch}.h2,h2{font-size:2.25rem;line-height:2.5rem}.h1,.h2+.h3,.h2+h3,h1,h2+.h3,h2+h3{margin-top:0}.h1,h1{font-size:2.75rem;line-height:3.5rem;margin-bottom:1rem;clear:both;font-weight:900;max-width:66ch}.h1+.h2,.h1+h2,h1+.h2,h1+h2{margin-top:0}a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}a:visited{color:#4c2c92}a:hover{color:#2e8aca}a:focus{outline:.25rem solid #0092a6;color:#005ea5}a:active{color:#222}.link--inverse{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.link--inverse:visited{color:#fff}.link--inverse:hover{color:#d6d6d6}.link--inverse:focus{outline:.25rem solid #fff;color:#fff}.link--inverse:active{color:#d6d6d6}.inverse-links a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.inverse-links a:visited{color:#fff}.inverse-links a:hover{color:#d6d6d6}.inverse-links a:focus{outline:.25rem solid #fff;color:#fff}.inverse-links a:active{color:#d6d6d6}.list,ol,ul{font-feature-settings:"kern","onum","liga";margin-left:1rem;max-width:66ch;padding:0}.list--unstyled{list-style:none;margin-left:0;max-width:none;padding:0}.list--loose .list__item,.list--loose li{margin-bottom:.25rem}.list--piped{list-style:none;margin-left:0;padding:0}.list--piped .list__item,.list--piped li{display:inline-block;margin-right:-.25rem}.list--piped .list__item a,.list--piped li a{padding:.5rem}.list--piped .list__item:after,.list--piped li:after{border-left:1px solid #004650;content:"\200B";display:inline-block;margin:0 .5em;overflow:hidden;text-indent:-99px;vertical-align:middle;width:0}.list--piped .list__item:first-child a,.list--piped li:first-child a{padding-left:0}.list--piped .list__item:last-child:after,.list--piped li:last-child:after{display:none}.quote{font-size:1.25rem;line-height:1.75rem;border-left:.25em solid #004650;font-weight:400;margin:2rem 0;padding:0 0 0 4rem;position:relative}.quote:before{color:#004650;content:"\201C";display:block;font-family:Arial,sans-serif;font-size:5rem;font-weight:700;left:0;line-height:.8;position:absolute;text-align:center;top:0;width:4rem}@media print{.quote:before{color:#000}}.quote p{font-size:inherit}.quote cite,.quote footer{font-size:1rem;line-height:1.5rem;font-style:normal}table{background:#fff;border:1px solid #adadad;border-collapse:collapse;display:block;margin:0 0 1rem;max-width:100%;overflow-y:hidden;overflow-x:auto;width:100%!important}table th{vertical-align:bottom}table td{vertical-align:top}table td,table th{border:1px solid #adadad;padding:.5rem;text-align:left}table td:first-child,table th:first-child{border-left:0}table td:last-child,table th:last-child{border-right:0}table td p,table th p{margin-top:0}table :not(thead)+tbody tr:first-child th,table tbody tr:first-child th,table thead tr:first-child th{border-top:0}table tbody tr:last-child td{border-bottom:0}table tbody tr:nth-child(2n)>td{background-color:#e9e9e9}html{overflow-x:visible;scroll-behavior:smooth}@media(prefers-reduced-motion){html{scroll-behavior:auto}}body{font-family:Lato,Trebuchet MS,Roboto,Helvetica Neue,Helvetica,Arial,sans-serif;position:relative}.visually-hidden{position:absolute;overflow:hidden;clip:rect(0 0 0 0);height:1px;width:1px;margin:-1px;padding:0;border:0}#content-start:focus{outline:none}footer{margin-top:0!important}@supports((position:-webkit-sticky) or (position:sticky)){.Layout-module--main--1OIFf{position:relative;padding-bottom:4rem}}.stacked-nav{background:#fff;border:1px solid #adadad;margin:0 0 2em}@media print{.stacked-nav{display:none!important}}.stacked-nav__root{font-size:1rem;line-height:1.5rem;border-bottom:1px solid #adadad;font-weight:700;margin:0;max-width:none;position:relative;text-decoration:none}.stacked-nav__root a{color:#222}.stacked-nav__root--no-link{padding:.5em}.stacked-nav__hint{color:#222;display:block}.stacked-nav__hint :active{color:#fff}.stacked-nav__list{list-style:none;margin:0;max-width:100%;padding:0}.stacked-nav__list-item{border-top:1px solid #adadad}.stacked-nav__content-wrapper{display:block}.stacked-nav a{color:#005ea5;display:block;padding:.5em;position:relative;text-decoration:none}.stacked-nav a[aria-current=page],.stacked-nav a[aria-current=true]{background:#e9e9e9;font-weight:700}.stacked-nav a[aria-current=page]:before,.stacked-nav a[aria-current=true]:before{background:#004650;content:"";display:block;height:100%;left:0;position:absolute;top:0;width:.25em}.stacked-nav a:hover{background:#d6d6d6}.stacked-nav a:active{background:#004650;color:#fff}.stacked-nav a:active span{color:#fff}.stacked-nav__nested{list-style:none;margin:0;padding:0}.stacked-nav__nested .stacked-nav__content-wrapper{padding-left:1rem!important}.stacked-nav__nested ul .stacked-nav__content-wrapper{padding-left:2rem!important}.TopicChaptersMenu-module--toggleButton--2MGXA{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:#e9e9e9;border:1px solid #adadad;color:#005ea5;cursor:pointer;display:block;margin:0 0 2rem;padding:1rem 2rem 1rem .5rem;position:relative;text-align:left;width:100%}.TopicChaptersMenu-module--toggleButton--2MGXA:focus{outline:.25rem solid #0092a6;z-index:1}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=false]+.stacked-nav{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]{border-bottom:0;margin:0}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]+.stacked-nav{display:block}@media(min-width:37.5em){.TopicChaptersMenu-module--toggleButton--2MGXA{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded]+.stacked-nav{display:block}}.TopicChaptersMenu-module--icon--27uSj{color:#005ea5;right:.5rem;position:absolute;top:50%;-webkit-transform:translateY(-50%);transform:translateY(-50%)}.ChapterContents-module--wrapper--3ONbu{position:relative}.ChapterContents-module--printBtn--Rk_Zs{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;bottom:100%;cursor:pointer;display:none;padding:0}.ChapterContents-module--printBtn--Rk_Zs:visited{color:#4c2c92}.ChapterContents-module--printBtn--Rk_Zs:hover{color:#2e8aca}.ChapterContents-module--printBtn--Rk_Zs:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterContents-module--printBtn--Rk_Zs:active{color:#222}.ChapterContents-module--printBtn--Rk_Zs svg{font-size:1.25rem;line-height:1.75rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterContents-module--printBtn--Rk_Zs:hover svg{color:#2e8aca}@media(min-width:37.5em){.ChapterContents-module--wrapper--3ONbu:after,.ChapterContents-module--wrapper--3ONbu:before{content:" ";display:table}.ChapterContents-module--wrapper--3ONbu:after{clear:both}.ChapterContents-module--menu--3Epka{float:left;margin-right:1rem;width:-webkit-calc(25% - .5rem);width:calc(25% - .5rem)}.ChapterContents-module--landing--3klSq,.ChapterContents-module--onThisPage--1333P{float:right;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + .5rem);overflow:hidden;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}}@media(min-width:56.25em){.ChapterContents-module--printBtn--Rk_Zs{display:block;margin-bottom:3rem;position:absolute;right:0}.ChapterContents-module--menu--3Epka{margin-right:2rem;width:-webkit-calc(25% - 1rem);width:calc(25% - 1rem)}.ChapterContents-module--landing--3klSq{width:-webkit-calc(75% - 1rem);width:calc(75% - 1rem)}.ChapterContents-module--onThisPage--1333P{position:-webkit-sticky;position:sticky;top:0;width:-webkit-calc(16.66667% - 1rem);width:calc(16.66667% - 1rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + 1rem);width:-webkit-calc(58.33333% - 2rem);width:calc(58.33333% - 2rem)}}@media print{.ChapterContents-module--menu--3Epka,.ChapterContents-module--onThisPage--1333P,.ChapterContents-module--printBtn--Rk_Zs{display:none}.ChapterContents-module--body--1XBoo{width:100%}}.ChapterBody-module--wrapper--2HCfk>.visually-hidden:first-child+*>:first-child{margin-top:0}.ChapterBody-module--wrapper--2HCfk h2:focus,.ChapterBody-module--wrapper--2HCfk h3:focus,.ChapterBody-module--wrapper--2HCfk h4:focus,.ChapterBody-module--wrapper--2HCfk h5:focus,.ChapterBody-module--wrapper--2HCfk h6:focus{outline:0!important}.ChapterBody-module--basisWrapper--3JBM_{border:1px solid #adadad;margin-top:1rem;max-width:66ch}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-top:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK{padding:0 1rem 1rem}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK>:last-child{margin-bottom:0}.ChapterBody-module--headerWrapper--qSIFw{padding:1rem;position:relative}.ChapterBody-module--toggleBtn--3g0p7{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;cursor:pointer;display:block;margin-top:-.5rem;padding:0}.ChapterBody-module--toggleBtn--3g0p7:visited{color:#4c2c92}.ChapterBody-module--toggleBtn--3g0p7:hover{color:#2e8aca}.ChapterBody-module--toggleBtn--3g0p7:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterBody-module--toggleBtn--3g0p7:active{color:#222}.ChapterBody-module--toggleBtn--3g0p7:after{content:"";height:100%;left:0;position:absolute;top:0;width:100%}.ChapterBody-module--toggleBtn--3g0p7 svg{font-size:1.125rem;line-height:1.5rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterBody-module--toggleBtn--3g0p7:hover svg{color:#2e8aca}.ChapterBody-module--body--2n0CK[aria-hidden=true]{display:none}@media print{.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-bottom:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK[aria-hidden=true]{display:block}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--toggleBtn--3g0p7{display:none}}.ChapterOnThisPage-module--wrapper--2zc7n{margin-bottom:2rem}.ChapterOnThisPage-module--heading--2SdDN{margin-top:0}.ChapterOnThisPage-module--rootList--2II70{list-style:disc}.ChapterOnThisPage-module--subList--Pwxy9{list-style:circle}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:none}@media(min-width:56.25em){.ChapterOnThisPage-module--heading--2SdDN{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:0}@supports((position:-webkit-sticky) or (position:sticky)){.ChapterOnThisPage-module--rootList--2II70 a[aria-current=location]{font-weight:700}.ChapterOnThisPage-module--rootList--2II70 a:focus+.ChapterOnThisPage-module--subList--Pwxy9{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--subList--Pwxy9{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.ChapterOnThisPage-module--subList--Pwxy9:focus-within{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--expandedSubList--1m1WN{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:list-item}}}</style><link rel="sitemap" type="application/xml" href="../../../../sitemap.xml"/><title data-react-helmet="true">Scenario: Chronic medical conditions | Management | Pre-conception - advice and management | CKS | NICE</title><link data-react-helmet="true" rel="search" type="application/opensearchdescription+xml" href="../../../../opensearch.xml" title="CKS"/><link data-react-helmet="true" rel="icon" href="../../../../favicon.ico"/><link data-react-helmet="true" rel="canonical" href="index.html"/><meta data-react-helmet="true" name="description" content="Covers specific issues to be considered in a woman with thyroid disease, diabetes mellitus, epilepsy, chronic cardiac disease, chronic hypertension, asthma, renal disease, venous thromboembolism, rheumatological conditions, inflammatory bowel disease, sickle cell disease, or thalassaemia who is planning a pregnancy."/><meta data-react-helmet="true" property="og:description" content="Covers specific issues to be considered in a woman with thyroid disease, diabetes mellitus, epilepsy, chronic cardiac disease, chronic hypertension, asthma, renal disease, venous thromboembolism, rheumatological conditions, inflammatory bowel disease, sickle cell disease, or thalassaemia who is planning a pregnancy."/><meta data-react-helmet="true" property="og:url" content="https://cks.nice.org.uk/topics/pre-conception-advice-management/management/chronic-medical-conditions/"/><meta data-react-helmet="true" property="og:locale" content="en_GB"/><meta data-react-helmet="true" property="og:type" content="website"/><meta data-react-helmet="true" property="og:title" content="Scenario: Chronic medical conditions | Management | Pre-conception - advice and management | CKS | NICE"/><meta data-react-helmet="true" property="og:image" content="https://cks.nice.org.uk/open-graph-image.png"/><meta data-react-helmet="true" property="og:image:width" content="1200"/><meta data-react-helmet="true" property="og:image:height" content="630"/><meta data-react-helmet="true" name="twitter:card" content="summary"/><meta data-react-helmet="true" name="twitter:image" content="https://cks.nice.org.uk/twitter-summary-image.png"/><meta data-react-helmet="true" name="twitter:image:alt" content="NICE and CKS logos"/><meta data-react-helmet="true" name="twitter:site" content="@NICEcomms"/><meta data-react-helmet="true" name="twitter:creator" content="@NICEcomms"/><meta data-react-helmet="true" name="theme-color" content="#004650"/><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+'';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer', 'GTM-54QC4NL');</script><link rel="manifest" href="../../../../manifest.webmanifest" crossorigin="anonymous"/><meta name="theme-color" content="#004650"/><link rel="apple-touch-icon" sizes="48x48" href="../../../../icons/icon-48x48.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="72x72" href="../../../../icons/icon-72x72.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="96x96" href="../../../../icons/icon-96x96.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="144x144" href="../../../../icons/icon-144x144.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="192x192" href="../../../../icons/icon-192x192.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="256x256" href="../../../../icons/icon-256x256.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="384x384" href="../../../../icons/icon-384x384.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="512x512" href="../../../../icons/icon-512x512.png@v=28734348209eeeae5c03a37867f1beb1"/><link as="script" rel="preload" href="../../../../webpack-runtime-28c424ef71f39faedaf0.js"/><link as="script" rel="preload" href="../../../../framework-34da02e39e1f104d9937.js"/><link as="script" rel="preload" href="../../../../app-53a71c38b210970893c4.js"/><link as="script" rel="preload" href="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js"/><link as="script" rel="preload" href="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js"/><link as="script" rel="preload" href="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"/><link as="fetch" rel="preload" href="../../../../page-data/topics/pre-conception-advice-management/management/chronic-medical-conditions/page-data.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/sq/d/3666801979.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/app-data.json" crossorigin="anonymous"/><script src="https://cdn.nice.org.uk/cookie-banner/cookie-banner.min.js" type="text/javascript" async=""></script></head><body><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54QC4NL" height="0" width="0" style="display: none; visibility: hidden" aria-hidden="true"></iframe></noscript><div id="___gatsby"><div style="outline:none" tabindex="-1" id="gatsby-focus-wrapper"><div><div class="Header-module--header--3os44"><header aria-label="Site header"><ul class="SkipLinks-module--list--1WwLa" aria-label="Accessibility links"><li><a href="index.html#content-start" class="SkipLinks-module--link--hkZw8">Skip to content</a></li><li><a href="https://www.nice.org.uk/accessibility" class="SkipLinks-module--link--hkZw8">Accessibility help</a></li></ul><div class="Header-module--container--1mfIr"><a href="https://www.nice.org.uk/" aria-label="Home" class="Header-module--home--1TCPb"><svg viewBox="0 0 4616 512" fill="none" class="Header-module--icon--4LSt5" aria-hidden="true" focusable="false"><path d="M1626 44v175h-22L1497 71v148h-19V44h22l107 147V44h19zm130 154a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-35 18-48 11-14 27-20 47-20 19 0 34 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm109 16V104h-27V87h27V40h19v47h30v17h-30v115h-19zm88-180v26h-21V39h21zm-20 48h20v132h-20V87zm107-2c20 0 35 6 48 20 11 12 17 28 17 48 0 19-6 36-17 48a61 61 0 01-48 20c-19 0-35-7-47-20a69 69 0 01-17-48c0-20 5-36 17-48 12-14 28-20 47-20zm0 118c14 0 25-5 34-15 7-9 11-21 11-35s-4-26-11-35c-9-10-20-15-34-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm107-116v21c5-7 11-12 18-17 6-4 14-6 23-6 8 0 16 1 22 4 6 2 12 6 17 11 10 10 16 24 16 42v77h-20v-76c0-13-3-22-10-29-7-8-16-11-26-11a38 38 0 00-40 40v76h-19V87h19zm222 111a52 52 0 01-46 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 5-35 17-48 12-14 27-20 47-20 19 0 35 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm114 16h-19V34h19v185zm108 0h-19V44h19v175zm55-132v21c5-7 10-12 17-17 7-4 15-6 23-6 9 0 17 1 23 4 6 2 12 6 16 11 11 10 16 24 16 42v77h-19v-76c0-13-4-22-10-29-7-8-16-11-27-11a38 38 0 00-39 40v76h-19V87h19zm202 35c-2-13-13-20-33-20s-30 6-30 19c0 5 2 9 6 12 5 2 10 5 16 6l21 5 21 7c7 2 12 6 16 11 5 5 7 11 7 19 0 13-5 23-15 30-9 7-22 10-38 10-18 0-32-4-42-13-9-8-14-18-15-31h20c2 13 8 21 21 25l13 2 13-1 11-3c8-3 12-9 12-17 0-5-2-9-6-12s-10-6-16-7l-21-5-21-7c-7-2-12-6-16-10-4-5-6-11-6-19 0-12 4-22 12-28 9-7 22-10 39-10 15 0 28 4 37 11 8 7 12 16 14 26h-20zm60 97V104h-26V87h26V40h20v47h30v17h-30v115h-20zm89-180v26h-21V39h21zm-21 48h20v132h-20V87zm65 132V104h-26V87h26V40h20v47h30v17h-30v115h-20zm162 0v-21c-4 7-10 12-17 16-7 5-14 7-23 7s-16-1-22-4c-7-2-12-6-17-11a57 57 0 01-16-42V87h20v76c0 12 3 22 10 29 6 7 15 11 26 11a39 39 0 0039-40V87h20v132h-20zm65 0V104h-26V87h26V40h20v47h30v17h-30v115h-20zm124-16c17 0 30-7 37-22h22c-5 12-12 22-22 29-9 7-22 11-38 11-19 0-35-7-47-20a68 68 0 01-18-48c0-20 5-36 17-48 12-14 28-20 47-20 20 0 35 6 48 20 11 12 17 28 17 48v8h-109c1 12 6 22 14 30s19 12 32 12zm-2-100c-12 0-22 4-30 11s-12 17-14 28h88c-1-11-6-21-14-28s-18-11-30-11zm195-52c-9 0-16 2-21 6-4 4-7 11-7 20v10h30v17h-30v115h-19V104h-23V87h23V75c0-14 4-25 12-32 9-7 21-11 36-11h1v19h-2zm75 34c19 0 35 6 47 20 12 12 18 28 18 48 0 19-6 36-18 48a61 61 0 01-47 20c-19 0-35-7-47-20a69 69 0 01-18-48c0-20 6-36 18-48 12-14 28-20 47-20zm0 118c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm156-118v20h-2c-14 0-25 5-34 17-9 11-13 24-13 39v58h-19V87h19v32c4-13 13-23 27-30 6-3 13-4 21-4h1zM1617 293v175h-19v-78h-101v78h-19V293h19v78h101v-78h19zm91 159c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c1 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm187 95a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-36 18-49 11-13 27-19 47-19 19 0 34 7 45 23v-21h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm114 16h-19V283h19v185zm46 0V353h-27v-17h27v-48h19v48h30v17h-30v115h-19zm87-185v73l17-16c7-4 15-6 24-6 8 0 16 1 22 3a58 58 0 0133 54v77h-20v-77c0-12-3-21-10-29-7-7-16-10-26-10a39 39 0 00-40 40v76h-19V283h19zm280 164a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm109-116v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 11 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10a39 39 0 00-39 40v76h-19V336h19zm222 111a52 52 0 01-47 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-74h19v185h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm233-1a56 56 0 0053-36h21c-6 17-15 30-28 39a82 82 0 01-50 16c-25 0-46-9-61-26a92 92 0 01-22-64c0-25 7-46 22-63 15-18 36-26 61-26a78 78 0 0178 54h-21c-4-11-11-19-20-25-10-7-20-10-33-10-12 0-22 2-30 5-9 4-15 9-21 15a73 73 0 00-17 50c0 21 6 37 17 50 12 14 29 21 51 21zm198-4a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 48-19 19 0 34 7 45 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm163-118v19h-2c-14 0-26 6-34 18-9 10-13 23-13 39v58h-19V336h19v32c4-14 13-24 27-30 6-3 13-4 21-4h1zm73 118c18 0 31-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-19 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 18-49s27-19 47-19c19 0 35 6 47 19s17 29 17 49v8h-109c2 12 7 22 15 30s19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm162-40v59h96v19h-96v59h108v19h-127V293h127v19h-108zm189 88l51 68h-25l-37-54-37 54h-25l51-68-48-64h25l34 50 33-50h25l-47 64zm120 52c9 0 16-3 23-7 6-5 11-11 14-19h21c-4 13-12 24-22 32-11 8-24 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19a60 60 0 0161 44h-20c-3-8-8-15-14-19-7-5-14-7-23-7-8 0-15 1-21 4-6 2-10 6-14 10-9 10-13 22-13 36s4 26 13 35c8 10 20 15 35 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-20 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 13-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm105 116h-19V283h19v185zm51 0h-20V283h20v185zm89-16c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c2 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm105-16v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 12 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10s-20 3-28 11c-7 7-11 17-11 29v76h-19V336h19zm185 116a40 40 0 0037-26h21c-4 13-12 24-22 32-11 8-25 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19c15 0 29 4 40 12 10 8 18 18 22 31h-21c-3-7-8-14-15-18-6-5-13-7-22-7-8 0-15 1-21 4-6 2-11 6-15 10-8 10-12 22-12 36s4 26 12 35c9 10 21 15 36 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 18 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-15 28h89c-2-11-6-21-14-28-8-8-18-11-30-11zM412 454c0 16-7 19-18 19h-53c-11 0-20-4-27-13L130 213h-2v242c0 13-6 18-18 18H52c-14 0-20-3-20-18V62c0-16 7-19 20-19h52c13 0 19 3 26 13l184 248h1V61c0-14 7-18 19-18h60c16 0 17 8 17 19v392h1zm197 4c0 7-5 14-14 14h-71c-9 0-14-7-14-14V56c0-8 5-15 14-15h71c9 0 14 7 14 14v403zm415-380l-18 52c-2 6-5 9-9 9l-8-2c-33-16-58-21-87-21-65 0-106 49-106 140 0 98 47 140 107 140 29 0 55-5 84-17l9-3c6 0 9 3 11 10l16 46 2 10c0 6-3 11-12 14-42 16-77 24-125 24-131 0-197-87-197-221S772 32 896 32c45 0 82 9 118 25 9 4 12 8 12 12l-2 9zm336-37c13 0 17 6 16 15l-6 50c-1 13-9 15-24 15h-149v93h140c14 0 19 7 19 17v45c0 12-7 18-18 18h-141v98h161c11 0 18 5 18 17v46c0 11-6 17-17 17h-240c-14 0-21-4-21-19V59c0-11 6-18 16-18h246z" fill="currentColor"></path></svg></a><div class="Header-module--wrapper--2e13D"><div class="Header-module--search--2nfnz"><form id="global-nav-search-form" role="search" action="https://cks.nice.org.uk/search" class="Search-module--search--2wNll"><label class="Search-module--label--1rrog" for="autocomplete">Search CKS…</label><div class="Autocomplete-module--ac--2PqiF"><div class="autocomplete__wrapper"><input type="search" id="autocomplete" name="q" class="autocomplete__input autocomplete__input--default" placeholder="Search CKS…" data-hj-allow="" maxLength="512" value=""/></div></div><button class="Search-module--button--2FbnI" type="submit" aria-label="Perform search"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="Search-module--icon--2JB42" aria-hidden="true" focusable="false"><path d="M83.784 476.472L197.112 363.16c30.144 20.32 65.056 30.528 100.032 30.528 45.904 0 91.776-17.488 126.8-52.528 70.064-70.064 70.064-183.584 0-253.616C388.936 52.504 343.048 35 297.144 35c-45.904 0-91.808 17.504-126.848 52.528-61.696 61.696-68.976 157.12-21.968 226.864L35 427.752l48.784 48.72zm213.36-137.952c-33.168 0-64.352-12.896-87.792-36.368-48.416-48.448-48.416-127.2 0-175.616 23.44-23.44 54.64-36.352 87.792-36.352s64.336 12.912 87.776 36.368c23.44 23.456 36.384 54.64 36.384 87.792s-12.928 64.352-36.384 87.792c-23.456 23.472-54.624 36.368-87.776 36.368v.016z" fill="currentColor"></path></svg></button></form></div><button class="Header-module--mobileMenuBtn--1LgyL" id="header-menu-button" type="button" aria-controls="header-menu" aria-expanded="false" aria-haspopup="menu" aria-label="Expand site menu">Menu</button></div></div><div id="header-menu" class="Nav-module--wrapper--2_xng Nav-module--wrapperWithSubLinks--3PUfX"><nav class="Nav-module--nav--2aQpa" aria-label="primary navigation"><div class="Nav-module--menuWrapper--2fp8S"><ul class="Nav-module--menuList--264L-" aria-labelledby="header-menu-button"><li><a href="https://pathways.nice.org.uk/" class="Nav-module--link--3JzDA">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Nav-module--link--3JzDA">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Nav-module--link--3JzDA">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Nav-module--link--3JzDA">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary">BNF<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Nav-module--link--3JzDA"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">Clinical Knowledge Summaries</span></a><div class="SubNav-module--wrapper--yAXWY"><ul class="SubNav-module--list--1K9bK" aria-label="CKS links"><li class="SubNav-module--imageLink--3xwIS"><a href="../../../../index.html" class="SubNav-module--link--39i23" aria-label="CKS - Home"><img src="data:image/svg+xml;base64,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" class="SubNav-module--image--uq-a2" alt=""/></a></li><li><a href="../../../index.html" class="SubNav-module--link--39i23" aria-label="Health topics A to Z">Health topics A to Z</a></li><li><a href="../../../../specialities/index.html" class="SubNav-module--link--39i23" aria-label="Specialities">Specialities</a></li><li><a href="../../../../whats-new/index.html" class="SubNav-module--link--39i23" aria-label="What&#x27;s new">What&#x27;s new</a></li><li><a href="../../../../about/index.html" class="SubNav-module--link--39i23" aria-label="About CKS">About CKS</a></li></ul></div></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Nav-module--link--3JzDA">Journals and databases</a></li></ul></div></nav></div></header><aside class="CoronaMessage-module--wrapper--zRiaV" aria-label="COVID-19 Notice"><div class="CoronaMessage-module--container--36Biz"><p>Read about<!-- --> <a href="https://www.nice.org.uk/covid-19">our approach to COVID-19</a></p></div></aside></div></div><main class="Layout-module--main--1OIFf" id="content-start"><div class="container"><nav aria-label="Breadcrumbs" role="navigation"><ol class="breadcrumbs"><li class="breadcrumbs__crumb"><a href="https://www.nice.org.uk/">NICE</a></li><li class="breadcrumbs__crumb"><a href="../../../../index.html">CKS</a></li><li class="breadcrumbs__crumb"><a href="../../../index.html">Health topics A to Z</a></li><li class="breadcrumbs__crumb"><a href="../../../../pre-conception-advice-and-management.html">Pre-conception - advice and management</a></li><li class="breadcrumbs__crumb"><a href="../index.html">Management</a></li><li class="breadcrumbs__crumb"><span>Scenario: Chronic medical conditions</span></li></ol></nav><script type="application/ld+json">{"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://www.nice.org.uk/","name":"NICE"}},{"@type":"ListItem","position":2,"item":{"@id":"/","name":"CKS"}},{"@type":"ListItem","position":3,"item":{"@id":"/topics/","name":"Health topics A to Z"}},{"@type":"ListItem","position":4,"item":{"@id":"/topics/pre-conception-advice-management/","name":"Pre-conception - advice and management"}},{"@type":"ListItem","position":5,"item":{"@id":"/topics/pre-conception-advice-management/management/","name":"Management"}},{"@type":"ListItem","position":6,"item":{"name":"Scenario: Chronic medical conditions"}}]}</script><div class="page-header"><h1 class="page-header__heading"><span class="page-header__pre-heading">Pre-conception - advice and management: </span><span>Scenario: Pre-conception advice - women with chronic medical conditions</span></h1><p class="page-header__lead"><span>Last revised in November 2019</span></p></div><p class="visually-hidden">Covers specific issues to be considered in a woman with thyroid disease, diabetes mellitus, epilepsy, chronic cardiac disease, chronic hypertension, asthma, renal disease, venous thromboembolism, rheumatological conditions, inflammatory bowel disease, sickle cell disease, or thalassaemia who is planning a pregnancy.</p><div class="ChapterContents-module--wrapper--3ONbu"><div class="ChapterContents-module--menu--3Epka"><nav class="stacked-nav" aria-label="Pre-conception - advice and management chapters"><ul class="stacked-nav__list"><li class="stacked-nav__list-item" data-tracking="Summary"><a aria-current="false" href="../../../../pre-conception-advice-and-management.html"><span class="stacked-nav__content-wrapper">Summary</span></a></li><li class="stacked-nav__list-item" data-tracking="Have I got the right topic?"><a aria-current="false" href="../../have-i-got-the-right-topic/index.html"><span class="stacked-nav__content-wrapper">Have I got the right topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="How up-to-date is this topic?"><a aria-current="false" href="../../how-up-to-date-is-this-topic/index.html"><span class="stacked-nav__content-wrapper">How up-to-date is this topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="Goals and outcome measures"><a aria-current="false" href="../../goals-outcome-measures/index.html"><span class="stacked-nav__content-wrapper">Goals and outcome measures</span></a></li><li class="stacked-nav__list-item" data-tracking="Background information"><a aria-current="false" href="../../background-information/index.html"><span class="stacked-nav__content-wrapper">Background information</span></a></li><li class="stacked-nav__list-item" data-tracking="Management"><a aria-current="false" href="../index.html"><span class="stacked-nav__content-wrapper">Management</span></a><ul class="stacked-nav__nested"><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Assessment"><a aria-current="false" href="../assessment/index.html"><span class="stacked-nav__content-wrapper">Scenario: Assessment</span></a></li><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Advice for all women"><a aria-current="false" href="../advice-for-all-women/index.html"><span class="stacked-nav__content-wrapper">Scenario: Advice for all women</span></a></li><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Mental health problems"><a aria-current="false" href="../mental-health-problems/index.html"><span class="stacked-nav__content-wrapper">Scenario: Mental health problems</span></a></li><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Chronic medical conditions"><a aria-current="true" class="" href="index.html"><span class="stacked-nav__content-wrapper">Scenario: Chronic medical conditions</span></a></li><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Genetic risk assessment"><a aria-current="false" href="../genetic-risk-assessment/index.html"><span class="stacked-nav__content-wrapper">Scenario: Genetic risk assessment</span></a></li></ul></li><li class="stacked-nav__list-item" data-tracking="Supporting evidence"><a aria-current="false" href="../../supporting-evidence/index.html"><span class="stacked-nav__content-wrapper">Supporting evidence</span></a></li><li class="stacked-nav__list-item" data-tracking="How this topic was developed"><a aria-current="false" href="../../how-this-topic-was-developed/index.html"><span class="stacked-nav__content-wrapper">How this topic was developed</span></a></li><li class="stacked-nav__list-item" data-tracking="References"><a aria-current="false" href="../../references/index.html"><span class="stacked-nav__content-wrapper">References</span></a></li></ul></nav></div><div class="ChapterContents-module--onThisPage--1333P"><nav class="ChapterOnThisPage-module--wrapper--2zc7n" aria-labelledby="on-this-page"><h2 class="ChapterOnThisPage-module--heading--2SdDN" id="on-this-page">On this page</h2><ol class="ChapterOnThisPage-module--rootList--2II70" aria-label="Jump links to section on this page"><li><a href="index.html#thyroid-disease">Thyroid disease</a><ol aria-label="Sections within Thyroid disease" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-9c3">Basis for recommendation</a></li></ol></li><li><a href="index.html#diabetes-mellitus">Diabetes mellitus</a><ol aria-label="Sections within Diabetes mellitus" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-5c5">Basis for recommendation</a></li></ol></li><li><a href="index.html#epilepsy">Epilepsy</a><ol aria-label="Sections within Epilepsy" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-45b">Basis for recommendation</a></li></ol></li><li><a href="index.html#chronic-cardiac-disease">Chronic cardiac disease</a><ol aria-label="Sections within Chronic cardiac disease" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-374">Basis for recommendation</a></li></ol></li><li><a href="index.html#chronic-hypertension">Chronic hypertension</a><ol aria-label="Sections within Chronic hypertension" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-c2a">Basis for recommendation</a></li></ol></li><li><a href="index.html#asthma">Asthma</a><ol aria-label="Sections within Asthma" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-c05">Basis for recommendation</a></li></ol></li><li><a href="index.html#renal-disease">Renal disease</a><ol aria-label="Sections within Renal disease" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-2f5">Basis for recommendation</a></li></ol></li><li><a href="index.html#venous-thromboembolism">Venous thromboembolism</a><ol aria-label="Sections within Venous thromboembolism" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-88f">Basis for recommendation</a></li></ol></li><li><a href="index.html#rheumatological-conditions">Rheumatological conditions</a><ol aria-label="Sections within Rheumatological conditions" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-eed">Basis for recommendation</a></li></ol></li><li><a href="index.html#inflammatory-bowel-disease">Inflammatory bowel disease</a><ol aria-label="Sections within Inflammatory bowel disease" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-6c7">Basis for recommendation</a></li></ol></li><li><a href="index.html#haemoglobinopathies">Haemoglobinopathies</a><ol aria-label="Sections within Haemoglobinopathies" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-e94">Basis for recommendation</a></li></ol></li></ol></nav></div><div class="ChapterContents-module--body--1XBoo"><section aria-labelledby="chronic-medical-conditions" class="ChapterBody-module--wrapper--2HCfk "><h2 id="chronic-medical-conditions" class="visually-hidden">Scenario: Pre-conception advice - women with chronic medical conditions</h2><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 1885b14f-22da-48ee-a9af-245d260ec49c --><!-- begin field a39b9413-2f5e-4c4b-aa48-acbd00863c82 --><p>From age 16 years to 45 years (Female).</p><!-- end field a39b9413-2f5e-4c4b-aa48-acbd00863c82 --><!-- end item 1885b14f-22da-48ee-a9af-245d260ec49c --></div><section aria-labelledby="thyroid-disease" class="ChapterBody-module--wrapper--2HCfk "><h3 id="thyroid-disease">How should I manage a woman with thyroid disease who wishes to become pregnant?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 9e45abcc-e7b5-4fe5-80ae-a7ae00e2387a --><!-- begin field cfe395cd-9c0c-46b3-a98d-a7ae00e23f2d --><ul><li>For more information on the management of a woman with:<ul><li>Hyperthyroidism who is planning a pregnancy — see the scenario: Preconception, pregnancy and postpartum in the CKS topic on <a class="topic-reference external-reference" href="../../../hyperthyroidism/index.html">Hyperthyroidism</a>.</li><li>Hypothyroidism or subclinical hypothyroidism who is planning a pregnancy — see the scenario: Preconception or pregnant in the CKS topic on <a class="topic-reference external-reference" href="../../../hypothyroidism/index.html">Hypothyroidism</a>. </li></ul></li><li>Offer general pre-pregnancy advice (see the <a class="topic-reference internal-reference" href="../advice-for-all-women/index.html">Scenario: Preconception advice for all women</a>).</li></ul><!-- end field cfe395cd-9c0c-46b3-a98d-a7ae00e23f2d --><!-- end item 9e45abcc-e7b5-4fe5-80ae-a7ae00e2387a --></div><section aria-labelledby="basis-for-recommendation-9c3" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-9c3">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 9c37af53-3c3d-4d6b-bb72-a7ae00e23fe0 --><!-- begin field 9e14a029-f1e0-4ded-a577-a7ae00e23fe0 --><p>The basis for the recommendations on pre-conception care for women with thyroid disease are discussed in the relevant sections in the CKS topics on <a class="topic-reference external-reference" href="../../../hyperthyroidism/index.html">Hyperthyroidism</a> and <a class="topic-reference external-reference" href="../../../hypothyroidism/index.html">Hypothyroidism</a>.</p><!-- end field 9e14a029-f1e0-4ded-a577-a7ae00e23fe0 --><!-- end item 9c37af53-3c3d-4d6b-bb72-a7ae00e23fe0 --></div></section></section><section aria-labelledby="diabetes-mellitus" class="ChapterBody-module--wrapper--2HCfk "><h3 id="diabetes-mellitus">How should I manage a woman with diabetes mellitus who wishes to become pregnant?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 5de96761-e482-433d-b8b6-a7ae00e32bbf --><!-- begin field bfab559a-db48-4920-b357-a7ae00e32eb5 --><ul><li><strong>Refer all women with diabetes mellitus who wish to become pregnant to a pre-conception diabetes clinic (if available) or to their diabetes care team, </strong>as soon as possible.<ul><li>Advise women planning a pregnancy that their blood glucose targets and current medication for diabetes and its complications will need to be reviewed.</li></ul></li><li><strong>Discuss the effect of diabetes on pregnancy, and pregnancy on diabetes.</strong> <ul><li>Pregnancy is associated with increased rates of hypoglycemia (and decreased hypoglycemic awareness), increased rates of diabetic ketoacidosis, and worsening of diabetic retinopathy and nephropathy. </li><li>Diabetes during pregnancy is associated with an increased risk of a number of adverse outcomes, including miscarriage, macrosomia and obstetric complications, developmental and growth abnormalities, and stillbirth. </li></ul></li><li><strong>Discuss the importance of optimal blood glucose control to reduce the risk of miscarriage, congenital malformation, stillbirth, and neonatal death.</strong><ul><li>The woman's glycosylated haemoglobin (HbA1c) level should be measured monthly. Pregnancy should be avoided if the HbA1c is above 86 mmol/mol (10%). </li><li>Women planning pregnancy should ideally aim to achieve a pre-conception HbA1c value of less than 48 mmol/mol (< 6.5%) if this can be achieved safely. Any reduction in HbA1c towards the normal HbA1c value of less than 48 mmol/mol (< 6.5%) is likely to reduce the risk of congenital malformations. <!--_c2a0_725_29_           --></li><li>Capillary plasma glucose target ranges should be considered to be the same as those recommended for all people with type 1 diabetes (a fasting plasma glucose level of 5–7 mmol/L on waking and a plasma glucose level of 4–7 mmol/L before meals at other times of the day). Goals for self-monitored glucose should take into account the risk of hypoglycaemia<strong>.</strong></li><li>Effective contraception methods should be used until a woman's individualized target has been achieved.<strong> </strong></li></ul></li><li><strong>Ensure that the woman is offered:</strong><ul><li>Individualized advice on diet and, if her body mass index is more than 27 kg/m<sup>2</sup>, advice on weight loss.</li><li>Advice to take folic acid 5 mg daily until week 12 of pregnancy. </li><li>Retinal assessment (unless she has had an annual retinal assessment in the last 6 months). Rapid optimisation of blood glucose levels should be avoided until assessment and any necessary treatment has been undertaken.</li><li>Renal assessment, including measuring for albuminuria, before stopping contraception. Referral to a nephrologist should be considered if serum creatinine is 120 micromol/L or more; the urinary albumin:creatinine ratio is more than 30 mg/mmol; or the estimated glomerular filtration rate (eGFR) is less than 45 mL/minute/1.73m<sup>2</sup>.</li></ul></li><li>Measure thyroid stimulating hormone (TSH), free thyroxine, and thyroid peroxidase antibodies in women with type 1 diabetes.<strong> </strong></li><li>Discuss other standard pre-conception measures (see <a class="topic-reference internal-reference" href="../advice-for-all-women/index.html">Advice for all women</a>).</li></ul><!-- end field bfab559a-db48-4920-b357-a7ae00e32eb5 --><!-- end item 5de96761-e482-433d-b8b6-a7ae00e32bbf --></div><section aria-labelledby="basis-for-recommendation-5c5" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-5c5">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 5c5149c4-6de3-4098-a0bc-a7ae00e32eb8 --><!-- begin field b2da0117-5cee-4526-bb15-a7ae00e32eb8 --><h5>Referral</h5><ul><li>This recommendation is based on expert opinion in a Diabetes UK position statement on <em>Preconception care for women with diabetes</em>. This states that a woman with diabetes should have access to members of the multidisciplinary team relevant to her needs (for example diabetologist, obstetrician, specialist diabetes dietitian, specialist diabetes nurse, and specialist diabetes midwife). The aim is to provide appropriate information to enable the woman to make informed decisions about her care [<a class="bibliography-reference internal-reference" href="../../references/index.html">Diabetes UK, 2015</a>].<strong> </strong>Expert opinion in a review article also describes pre-conception diabetic care as a multidisciplinary approach [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lassi et al, 2014</a>].<strong> </strong></li></ul><h5>Reviewing blood glucose targets and concurrent medication</h5><ul><li>This recommendation is extrapolated from a National Institute for Health and Care Excellence guideline on <em>Diabetes in pregnancy: management from preconception to the postnatal period</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015</a>], a Diabetes UK position statement on <em>Preconception care for women with diabetes</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Diabetes UK, 2015</a>], and expert opinion in a review article [<a class="bibliography-reference internal-reference" href="../../references/index.html">Callegari et al, 2015</a>].<ul><li>Data are extremely limited for the use of antidiabetic drugs other than metformin during pregnancy [<a class="bibliography-reference internal-reference" href="../../references/index.html">UKTIS, 2016</a>], therefore, oral blood glucose-lowering drugs (except metformin) should be stopped before pregnancy and replaced with insulin [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015</a>].<strong> </strong>There is no evidence that metformin is associated with an<strong> </strong>increased risk of congenital malformations or other adverse pregnancy outcomes [<a class="bibliography-reference internal-reference" href="../../references/index.html">UKTIS, 2011c</a>]. </li><li>Studies suggest that, in the second half of pregnancy, angiotensin-converting enzyme inhibitors (ACE inhibitors) are associated with reduced placental circulation, fetal hypotension, oligohydramnios, and anuria in the neonate, and that angiotensin II receptor antagonists (AIIRAs) have similar risks [<a class="bibliography-reference internal-reference" href="../../references/index.html">Schaefer, 2015</a>]. ACE inhibitors and AIIRAs should therefore be stopped both in women planning pregnancy and during pregnancy [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2010</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015</a>].</li><li>Statins should be discontinued prior to pregnancy [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015</a>]. The mother is unlikely to be harmed by temporarily stopping these drugs when used for primary prevention, and one study and an analysis of case reports suggest an association with statin use and fetal nervous system and limb defects, although the risk is unclear as a number of studies did not report an increase in malformations [<a class="bibliography-reference internal-reference" href="../../references/index.html">Schaefer, 2015</a>]. </li></ul></li></ul><h5>Discussing the effects of diabetes on pregnancy, and pregnancy on diabetes</h5><ul><li>CKS recommends discussing with the woman the implications of her diabetes and her pregnancy based on the NICE guideline on <em>Diabetes in pregnancy: management from preconception to the postnatal period</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015</a>],<strong> </strong>expert opinion in a Diabetes UK position statement on <em>Preconception care for women with diabetes </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Diabetes UK, 2015</a>], and expert opinion in review articles [<a class="bibliography-reference internal-reference" href="../../references/index.html">Farahi and Zolotor, 2013</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Lassi et al, 2014</a>].</li></ul><h5>Discussing the importance of optimal blood glucose control</h5><ul><li>This recommendation is based on the NICE guideline on <em>Diabetes in pregnancy: management from preconception to the postnatal period</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015</a>]<strong> </strong>and a position paper from the American Academy of Family Physicians [<a class="bibliography-reference internal-reference" href="../../references/index.html">AAFP, 2015</a>].<ul><li>There is a correlation between increasing maternal hyperglycaemia and maternal and fetal adverse outcomes. The risks of uncontrolled diabetes in pregnancy include progression of retinopathy or nephropathy, pre-eclampsia, congenital malformations, fetal macrosomia, preterm delivery, and complications with delivery (for example shoulder dystocia), intrauterine death, and neonatal hypoglycaemia [<a class="bibliography-reference internal-reference" href="../../references/index.html">UKTIS, 2011d</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">AAFP, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">UKTIS, 2016</a>]. </li></ul></li></ul><h5>HbA1c measurement and levels, and capillary plasma glucose target ranges</h5><ul><li>The recommendations on HbA1c measurement, HbA1c levels, and capillary plasma glucose target ranges reflect those in the NICE guideline on <em>Diabetes in pregnancy: management from preconception to the postnatal period</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015</a>], information in a Diabetes UK position statement on <em>Preconception care for women with diabetes </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Diabetes UK, 2015</a>]<strong> </strong>and expert opinion in a review article [<a class="bibliography-reference internal-reference" href="../../references/index.html">Callegari et al, 2015</a>].<ul><li>UKTIS advises close monitoring of maternal glucose levels during pregnancy because of changing insulin requirements throughout pregnancy that need frequent assessment [<a class="bibliography-reference internal-reference" href="../../references/index.html">UKTIS, 2011d</a>]. </li></ul></li></ul><h5>Advice on diet and weight</h5><ul><li>This recommendation is based on the NICE guideline on <em>Diabetes in pregnancy: management from preconception to the postnatal period</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015</a>].</li></ul><h5>Folic acid</h5><ul><li>NICE and the British National Formulary consider women with diabetes mellitus to be at high risk of conceiving a child with a neural tube defect. The recommended dose of folic acid for this group is 5 mg daily from before conception until 12 weeks of gestation [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">BNF 73, 2017</a>], consistent with advice from the UK Teratology Information Service in their monograph on <em>Diabetes Mellitus in Pregnancy </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">UKTIS, 2011e</a>].</li></ul><h5>Offering retinal and renal assessment</h5><ul><li>These recommendations on retinal and renal assessment in a woman with diabetes planning a pregnancy reflect the NICE guideline on <em>Diabetes in pregnancy: management from preconception to the postnatal period</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015</a>].<ul><li>If a woman has diabetic retinopathy it can progress more quickly during pregnancy [<a class="bibliography-reference internal-reference" href="../../references/index.html">Diabetes UK, 2015</a>]<strong> </strong>and there is evidence to suggest that rapid optimisation of glycaemic control can cause deterioration of diabetic retinopathy<strong> </strong>[<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women&#39;s and Children&#39;s Health, 2015</a>]. </li></ul></li></ul><h5>Measurement of thyroid function</h5><ul><li>The recommendation to test thyroid function is based on expert opinion in a UK consensus guideline produced by the Association for Clinical Biochemistry, British Thyroid Association, and the British Thyroid Foundation [<a class="bibliography-reference internal-reference" href="../../references/index.html">BTA et al, 2006</a>]. </li></ul><!-- end field b2da0117-5cee-4526-bb15-a7ae00e32eb8 --><!-- end item 5c5149c4-6de3-4098-a0bc-a7ae00e32eb8 --></div></section></section><section aria-labelledby="epilepsy" class="ChapterBody-module--wrapper--2HCfk "><h3 id="epilepsy">How do I manage a woman with epilepsy who wishes to become pregnant?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 09aa42ab-1e30-4bb6-842c-c008bbf188b8 --><!-- begin field acbd6cc7-594d-4ae1-8a6d-b69095a8c267 --><ul><li><strong>Reassure the woman </strong>that, even on anti-epileptic medication, she is likely to have a normal pregnancy and healthy baby.</li><li><strong>Refer all women with epilepsy to a specialist</strong> <strong>before conceiving.</strong><ul><li>Advise the woman to continue using effective contraception until a full assessment by the specialist has taken place. </li><li>Advise the woman not to stop taking her medication unless otherwise directed by the specialist.</li></ul></li><li>Discuss the standard pre-conception measures (see <a class="topic-reference internal-reference" href="../advice-for-all-women/index.html">Advice for all women</a>).<ul><li>Women taking antiepileptic drugs are considered to be at high risk of conceiving a child with a neural tube defect and should be prescribed folic acid 5 mg daily until the twelfth week of pregnancy.</li></ul></li></ul><!-- end field acbd6cc7-594d-4ae1-8a6d-b69095a8c267 --><!-- end item 09aa42ab-1e30-4bb6-842c-c008bbf188b8 --></div><section aria-labelledby="basis-for-recommendation-45b" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-45b">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 45bac0ab-2bc0-4868-a5b6-5d424c82c629 --><!-- begin field be280fec-db65-4aff-9149-50eda9898da6 --><h5>Reassurance</h5><ul><li>This recommendation is based on guidelines from the Royal College of Obstetricians and Gynaecologists (RCOG) on <em>Epilepsy in pregnancy</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCOG, 2016b</a>],<strong> </strong>and the Scottish Intercollegiate Guidelines Network (SIGN) on<em> Diagnosis and management of epilepsy in adults </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">SIGN, 2015</a>].</li><li>There is evidence to suggest that most women with epilepsy will experience improved seizure frequency or no change during pregnancy, with around half having no seizures during pregnancy [<a class="bibliography-reference internal-reference" href="../../references/index.html">SIGN, 2015</a>]. </li></ul><h5>Referral</h5><ul><li>Referral is important to allow an epilepsy specialist to review the diagnosis, assess the risk to the fetus of current medication, ensure optimal seizure control before conception, and discuss any genetic factors. This recommendation is based on an RCOG guideline on <em>Epilepsy in pregnancy</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCOG, 2016b</a>], and a guideline from the Scottish Intercollegiate Guidelines Network (SIGN) on <em>Diagnosis and management of epilepsy in adults </em>that advises women should receive a review by specialist services before conceiving [<a class="bibliography-reference internal-reference" href="../../references/index.html">SIGN, 2015</a>].<ul><li>Good seizure control before conception increases the likelihood of seizure control during pregnancy [<a class="bibliography-reference internal-reference" href="../../references/index.html">SIGN, 2015</a>]. </li></ul></li><li>Pregnancy in women with epilepsy is associated with a higher risk of congenital abnormalities compared with women who do not have epilepsy. However, these malformations are associated with the use of antiepileptic drugs (AEDs) rather than epilepsy itself [<a class="bibliography-reference internal-reference" href="../../references/index.html">Schaefer, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">SIGN, 2015</a>].<ul><li>The most common major malformations associated with AEDs include neural tube defects, orofacial defects, congenital heart disorders, urinary tract and skeletal abnormalities [<a class="bibliography-reference internal-reference" href="../../references/index.html">Schaefer, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">RCOG, 2016b</a>].</li><li> The risk of fetal congenital abnormalities depends on the type, number, and dose of AEDs taken [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCOG, 2016b</a>]. Sodium valproate has been associated with a significantly higher risk of malformations than other AEDs [<a class="bibliography-reference internal-reference" href="../../references/index.html">Schaefer, 2015</a>]. </li></ul></li></ul><h5>Contraception</h5><ul><li>This recommendation is based on expert opinion that contraception should be used by women with epilepsy prior to reviewing and optimising their medication in relation to fetal toxicity because of the potential teratogenic risks of AEDs [<a class="bibliography-reference internal-reference" href="../../references/index.html">Schaefer, 2015</a>]. </li></ul><h5>Advice not to stop medication unless advised by a specialist</h5><ul><li>Expert opinion in a textbook suggests that stable medication should not be quickly stopped or altered during pregnancy [<a class="bibliography-reference internal-reference" href="../../references/index.html">Schaefer, 2015</a>].<strong> </strong>A pregnant woman with epilepsy and her fetus are at risk from the effect of seizures as well as the teratogenic effects of AEDs [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lassi et al, 2014</a>].<strong> </strong>The SIGN guideline on <em>Diagnosis and management of epilepsy in adults </em>reflects this, stating that poor adherence with AED treatment during pregnancy may lead to problems with seizures [<a class="bibliography-reference internal-reference" href="../../references/index.html">SIGN, 2015</a>]. </li></ul><h5>Dose of folic acid in women taking antiepileptic drugs</h5><ul><li>This is based on recommendations in the guidelines <em>Epilepsies: diagnosis and management </em>commissioned by the National Institute for Health and Care Excellence (NICE) [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2012a</a>]<strong> </strong>and <em>Diagnosis and management of epilepsy in adults</em><strong> </strong>from<strong> </strong>the Scottish Intercollegiate Guidelines Network (SIGN), which states that a higher dose of folic acid is advisable for women with epilepsy needing AED treatment because several AEDs are folate antagonists<em> </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">SIGN, 2015</a>].<strong> </strong>This is also supported by dosing recommendations in the British National Formulary<strong> </strong>[<a class="bibliography-reference internal-reference" href="../../references/index.html">BNF 73, 2017</a>].</li><li>The RCOG guideline on<em> Epilepsy in pregnancy</em> advises that 'all' women with epilepsy, receive 5 mg of folic acid [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCOG, 2016b</a>]. This is at variance with other guidelines that only advise the higher 5 mg folic acid dose for women on AEDs. </li></ul><!-- end field be280fec-db65-4aff-9149-50eda9898da6 --><!-- end item 45bac0ab-2bc0-4868-a5b6-5d424c82c629 --></div></section></section><section aria-labelledby="chronic-cardiac-disease" class="ChapterBody-module--wrapper--2HCfk "><h3 id="chronic-cardiac-disease">How do I manage a woman with chronic cardiac disease who wishes to become pregnant?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 7dd185c4-67e0-4996-b7da-237912131b98 --><!-- begin field 2b5f440a-a3cb-47ce-a205-ffbf5c55f5f8 --><ul><li><strong>Refer all women with cardiac disease who wish to become pregnant to a cardiologist </strong>for accurate diagnosis and functional assessment so that maternal and fetal risk can be assessed.<ul><li>Advise the woman to continue using effective contraception until a full assessment by the cardiologist has taken place.</li><li>Advise the woman not to stop taking her medication unless otherwise directed by the cardiologist.</li></ul></li><li>Discuss the standard pre-conception measures (see <a class="topic-reference internal-reference" href="../advice-for-all-women/index.html">Advice for all women</a>).</li></ul><!-- end field 2b5f440a-a3cb-47ce-a205-ffbf5c55f5f8 --><!-- end item 7dd185c4-67e0-4996-b7da-237912131b98 --></div><section aria-labelledby="basis-for-recommendation-374" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-374">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 374801df-bc44-4068-937b-1228942b558a --><!-- begin field 16dd7c9d-84af-4998-a9eb-be7a7479685c --><h5>Referral to a cardiologist</h5><ul><li>CKS recommends referral to a specialist for women with cardiac disease on the basis of expert opinion in review articles which consider specialist care to be essential for women with pre-existing heart disease planning a pregnancy [<a class="bibliography-reference internal-reference" href="../../references/index.html">Seshadri et al, 2012</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Callegari et al, 2015</a>]. Heart disease is the most common cause of maternal death in the UK [<a class="bibliography-reference internal-reference" href="../../references/index.html">Seshadri et al, 2012</a>].</li><li>All women with chronic cardiac disease should undergo accurate diagnostic and functional evaluation prior to pregnancy, in order to predict maternal and fetal risk as far as possible [<a class="bibliography-reference internal-reference" href="../../references/index.html">Head, 2010</a>]:<ul><li>A woman's functional capacity preconception is an important predictor of her ability to tolerate pregnancy.</li><li>Women with pulmonary hypertension, an aortic aneurysm, severe aortic stenosis, or symptomatic ventricular dysfunction should be advised against becoming pregnant.</li></ul></li></ul><h5>Continuing with contraception until assessment by a cardiologist</h5><ul><li>This recommendation is pragmatic and is extrapolated from expert opinion in a review article suggesting that the woman should have a pre-conception discussion with a cardiologist before becoming pregnant [<a class="bibliography-reference internal-reference" href="../../references/index.html">Callegari et al, 2015</a>]. </li></ul><h5>Advice not to stop medication unless advised by a cardiologist</h5><ul><li>CKS pragmatically advises not stopping medication unless advised by a cardiologist based on expert opinion in a textbook advising that treatment with cardiac drugs should be reviewed before conception [<a class="bibliography-reference internal-reference" href="../../references/index.html">Head, 2010</a>]. </li></ul><!-- end field 16dd7c9d-84af-4998-a9eb-be7a7479685c --><!-- end item 374801df-bc44-4068-937b-1228942b558a --></div></section></section><section aria-labelledby="chronic-hypertension" class="ChapterBody-module--wrapper--2HCfk "><h3 id="chronic-hypertension">How do I manage a woman with chronic hypertension who wishes to become pregnant?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item dc97ff6d-f9f2-4e41-8941-307c88c9929c --><!-- begin field fd5299f0-7570-48d8-b4ce-786b2bb6ab10 --><ul><li><strong>Refer all women with a history of hypertension who wish to become pregnant </strong>to a specialist in hypertensive disorders prior to becoming pregnant.<ul><li>Advise the woman that she will be at increased risk of pre-eclampsia during pregnancy and that she will require careful monitoring.</li><li>Advise the woman to continue using effective contraception until she has been fully assessed.</li><li>Advise the woman not to stop taking her current medication unless directed by the specialist. </li></ul></li><li>Discuss the standard pre-conception measures (see <a class="topic-reference internal-reference" href="../advice-for-all-women/index.html">Advice for all women</a>).</li><li>For more information on the management of women with hypertension who are already pregnant, see the CKS topic on <a class="topic-reference external-reference" href="../../../../hypertension-in-pregnancy.html">Hypertension in pregnancy</a>.</li></ul><!-- end field fd5299f0-7570-48d8-b4ce-786b2bb6ab10 --><!-- end item dc97ff6d-f9f2-4e41-8941-307c88c9929c --></div><section aria-labelledby="basis-for-recommendation-c2a" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-c2a">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item c2a6fc84-757d-400d-aa2b-b3f99dba40c4 --><!-- begin field 1f2cd5c1-c42a-4b49-afa7-ed3edc697d1b --><h5>Referral</h5><ul><li>CKS recommends referral to a specialist in hypertensive disorders for women with chronic hypertension planning a pregnancy because hypertension during pregnancy increases the risks for the mother and baby and adjustments to the woman's medication and assessment for end organ damage prior to pregnancy may be required [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2010b</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Farahi and Zolotor, 2013</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Callegari et al, 2015</a>]. The recommendation is also extrapolated from the expert opinion of the National Institute for Health and Care Excellence <em>Hypertension in pregnancy </em>guideline development group that suggests referral to a specialist in hypertensive disorders (for example obstetric physician, renal physician, endocrinologist) for women who are already pregnant who have secondary chronic hypertension [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women&#39;s and Children&#39;s Health, 2010</a>].<ul><li>If a woman has chronic hypertension, pregnancy is associated with an increased risk of hypertensive disorders of pregnancy (such as pre-eclampsia), placental abruption, intrauterine growth retardation, preterm birth and fetal loss [<a class="bibliography-reference internal-reference" href="../../references/index.html">Farahi and Zolotor, 2013</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Lassi et al, 2014</a>].<strong> </strong>Hypertension in pregnancy is one of the most common causes of maternal death in the UK [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2010b</a>].</li><li>A National Institute for Health and Care Excellence guideline on <em>Hypertension in pregnancy: diagnosis and management </em>emphasises the need to discuss hypertensive treatment if planning a pregnancy. Angiotensin converting-enzyme inhibitors and angiotensin II receptor blockers increase the risk of congenital abnormalities if taken in pregnancy [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2010b</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">UKTIS, 2013</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">UKTIS, 2015</a>]<strong> </strong>and expert opinion suggests they should be avoided in women planning pregnancy and during pregnancy [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women&#39;s and Children&#39;s Health, 2010</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">AAFP, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Callegari et al, 2015</a>]. Safer alternative treatments should be discussed if pregnancy is being planned [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women&#39;s and Children&#39;s Health, 2010</a>]. For more information, see the CKS topic on <a class="topic-reference external-reference" href="../../../../hypertension-in-pregnancy.html">Hypertension in pregnancy</a>.</li><li>The American Academy of Family Physicians position paper on <em>Preconception care</em> notes the need for a pre-conception assessment for renal disease, retinopathy, and ventricular hypertrophy in women with chronic hypertension [<a class="bibliography-reference internal-reference" href="../../references/index.html">AAFP, 2015</a>].<strong> </strong>This is supported by expert opinion in review articles [<a class="bibliography-reference internal-reference" href="../../references/index.html">Farahi and Zolotor, 2013</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Callegari et al, 2015</a>]. </li></ul></li></ul><h5>Increased risk of pre-eclampsia</h5><ul><li>This recommendation is based on an American Academy of Family Physicians position paper on<em> Preconception care</em> that advises counselling about pre-eclampsia for women with chronic hypertension [<a class="bibliography-reference internal-reference" href="../../references/index.html">AAFP, 2015</a>]. There is evidence that pre-eclampsia is more common in women with chronic hypertension [<a class="bibliography-reference internal-reference" href="../../references/index.html">Farahi and Zolotor, 2013</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Lassi et al, 2014</a>]. </li></ul><h5>Using effective contraception until fully assessed</h5><ul><li>This recommendation is pragmatic and is based on what CKS considers to be good clinical practice. Avoiding pregnancy until a full assessment has taken place allows the risks of hypertension and medication to be evaluated and any necessary pre-conception adjustments to be made, with the aim of optimising the chance of a healthy pregnancy. </li></ul><h5>Not stopping medication unless directed by a specialist </h5><ul><li>CKS has extrapolated this recommendation from evidence in a review article and a systematic review on the risks of chronic hypertension in pregnancy, including preterm birth, placental abruption, intrauterine growth restriction and fetal loss. The woman is also at increased risk of worsening hypertension, endorgan damage, and pre-eclampsia. Although there is no evidence that perinatal outcomes are improved by treating mild to moderate hypertension in pregnancy, treatment of severe hypertension has been shown to improve pregnancy outcomes [<a class="bibliography-reference internal-reference" href="../../references/index.html">Farahi and Zolotor, 2013</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Lassi et al, 2014</a>].<strong> </strong>The NICE guideline <em>Hypertension in pregnancy: diagnosis and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2010b</a>] provides the following advice:<ul><li>In pregnant women with uncomplicated chronic hypertension, aim to keep blood pressure lower than 150/100 mmHg.</li><li>Do not offer pregnant women with uncomplicated chronic hypertension treatment to lower diastolic blood pressure below 80 mmHg.</li><li>Offer pregnant women with target-organ damage secondary to chronic hypertension (for example, kidney disease) treatment with the aim of keeping blood pressure lower than 140/90 mmHg.</li></ul></li></ul><!-- end field 1f2cd5c1-c42a-4b49-afa7-ed3edc697d1b --><!-- end item c2a6fc84-757d-400d-aa2b-b3f99dba40c4 --></div></section></section><section aria-labelledby="asthma" class="ChapterBody-module--wrapper--2HCfk "><h3 id="asthma">How do I manage a woman with asthma who wishes to become pregnant?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 673c3109-9b69-4634-8fa9-a18131110d5f --><!-- begin field 4adbef8d-9947-4269-b819-cc9e23798e09 --><ul><li><strong>For women with mild asthma, </strong>ensure that asthma is well controlled.</li><li><strong>For women with moderate or severe asthma and those in whom asthma is poorly controlled, </strong>refer to a chest physician to ensure adequate control and monitoring.</li><li><strong>Discuss the importance of continuing to take asthma medication as prescribed,</strong> both before conception and throughout the pregnancy, to maintain good asthma control.<ul><li>Treatment of controlled asthma requires little modification in pregnancy. The risks from uncontrolled asthma are much greater than the risk from asthma treatment during pregnancy.</li><li>Steroid tablets should be used as normal in the pre-conception period and during pregnancy and never withheld because of pregnancy.</li></ul></li><li>Discuss the standard pre-conception measures (see <a class="topic-reference internal-reference" href="../advice-for-all-women/index.html">Advice for all women</a>).</li><li>For further details of asthma management see the CKS topic on <a class="topic-reference external-reference" href="../../../asthma/index.html">Asthma</a>.</li></ul><!-- end field 4adbef8d-9947-4269-b819-cc9e23798e09 --><!-- end item 673c3109-9b69-4634-8fa9-a18131110d5f --></div><section aria-labelledby="basis-for-recommendation-c05" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-c05">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item c05402a1-20f5-446d-b67c-7c2216193e47 --><!-- begin field ce3af116-227e-48b6-80ea-9e44d8452b1f --><h5>Ensuring that mild asthma is well controlled</h5><ul><li>This recommendation is based on expert opinion that if asthma is poorly controlled before pregnancy, a woman is more likely to have worsening symptoms when pregnant [<a class="bibliography-reference internal-reference" href="../../references/index.html">Farahi and Zolotor, 2013</a>]. </li></ul><h5>Referring women with moderate, severe or poorly-controlled asthma</h5><ul><li>The <em>British guideline on the management of asthma</em> from the Scottish Intercollegiate Guidelines Network (SIGN) and British Thoracic Society (BTS) states that pregnant women with moderate to severe asthma should be closely monitored to attain good control and minimise problems for the woman and her baby [<a class="bibliography-reference internal-reference" href="../../references/index.html">BTS/SIGN, 2016</a>].</li><li>Women with severe asthma are more likely than those with mild asthma to experience worsening of symptoms during pregnancy [<a class="bibliography-reference internal-reference" href="../../references/index.html">BTS/SIGN, 2016</a>].</li><li>CKS also recommends referral of women with poorly-controlled asthma, as, in pregnancy, this group have an increased risk of complications for both the mother and the fetus, including hyperemesis, pre-eclampsia, fetal growth restriction, complicated labour, pre-term birth, low birth weight, and perinatal mortality. Prospective analyses show that for women with well-controlled asthma, there is only a small, or no, increase in risk for the mother and baby [<a class="bibliography-reference internal-reference" href="../../references/index.html">Farahi and Zolotor, 2013</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Lassi et al, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">BTS/SIGN, 2016</a>].</li></ul><h5>Continuing asthma medication</h5><ul><li>This recommendation is based on the SIGN/BTS <em>British guideline on the management of asthma</em><strong> </strong>which advises counselling women with asthma on the importance and safety of continuing their treatment during pregnancy [<a class="bibliography-reference internal-reference" href="../../references/index.html">BTS/SIGN, 2016</a>].<ul><li>Generally, medicines used to treat asthma in pregnancy are considered to be safe and the risks of treatment are outweighed by the risk of harm from severe, uncontrolled, or chronically undertreated asthma [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lassi et al, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">BTS/SIGN, 2016</a>].<strong> </strong></li><li>There is sufficient experience with long-acting and short-acting beta2-agonists, inhaled corticosteroids, sodium cromoglicate, nedocromil sodium and theophylline (check blood levels) to recommend their use as normal during pregnancy [<a class="bibliography-reference internal-reference" href="../../references/index.html">BTS/SIGN, 2016</a>].</li><li>There is limited data on the use of leukotriene receptor antagonists during pregnancy, but the SIGN and BTS guidelines recommend that they may be continued during pregnancy if they are needed to achieve adequate control of asthma [<a class="bibliography-reference internal-reference" href="../../references/index.html">BTS/SIGN, 2016</a>].</li><li>There are concerns that oral corticosteroids taken in the first trimester of pregnancy may be associated with oral clefts, but data are conflicting. Even if this association is real it is important to treat exacerbations of acute asthma in pregnancy as the benefits outweigh the risks to the mother and the fetus. Prednisolone is the preferred oral corticosteroid as little crosses the placenta [<a class="bibliography-reference internal-reference" href="../../references/index.html">BTS/SIGN, 2016</a>].</li></ul></li></ul><!-- end field ce3af116-227e-48b6-80ea-9e44d8452b1f --><!-- end item c05402a1-20f5-446d-b67c-7c2216193e47 --></div></section></section><section aria-labelledby="renal-disease" class="ChapterBody-module--wrapper--2HCfk "><h3 id="renal-disease">How should I manage a woman with renal disease who wishes to become pregnant?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 0bbb4969-7f1c-4738-bbdc-be335d6674ee --><!-- begin field efd68830-1c7a-4ab9-a5d9-777a5b9f0992 --><ul><li><strong>Refer women who have renal disease and are planning a pregnancy</strong> to a specialist for assessment.<ul><li>Advise the woman to continue using effective contraception until she has been fully assessed.</li><li>Advise the woman not to stop taking her current medication unless otherwise directed by the specialist.</li></ul></li><li>Discuss the standard pre-conception measures (see <a class="topic-reference internal-reference" href="../advice-for-all-women/index.html">Advice for all women</a>).</li></ul><!-- end field efd68830-1c7a-4ab9-a5d9-777a5b9f0992 --><!-- end item 0bbb4969-7f1c-4738-bbdc-be335d6674ee --></div><section aria-labelledby="basis-for-recommendation-2f5" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-2f5">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 2f577f80-1a9a-41fd-8df5-b67018b19c56 --><!-- begin field 7556cac6-2471-450b-99c5-a0105e825af7 --><h5>Referral</h5><ul><li>CKS has based this recommendation on expert opinion in review articles that there are a number of adverse outcomes associated with maternal renal disease in pregnancy, including [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lassi et al, 2014</a>]:<ul><li>For the mother — pre-eclampsia, anaemia, caesarean delivery, exacerbation of renal disease.</li><li>For the fetus — growth restriction, preterm delivery, miscarriage and stillbirth.</li></ul></li><li>Expert opinion suggests that a multidisciplinary team approach may be required to control disease activity prior to conception, optimise blood pressure, and ensure treatments are reviewed and are relatively safe for the mother and fetus [<a class="bibliography-reference internal-reference" href="../../references/index.html">Bramham and Lightstone, 2012</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Palma-Reis et al, 2013</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Smyth et al, 2013</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Wiles et al, 2015</a>].</li><li>A cross-sectional assessment of 72 women with chronic kidney disease attending a pre-pregnancy counselling clinic found that about 90% found it informative and helped with their decision making about pregnancy [<a class="bibliography-reference internal-reference" href="../../references/index.html">Wiles et al, 2015</a>].</li></ul><h5>Contraception</h5><ul><li>This recommendation is based on expert opinion that suggests planning pregnancy for the right time, when renal disease is stable and after a period of remission [<a class="bibliography-reference internal-reference" href="../../references/index.html">Bramham and Lightstone, 2012</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Smyth et al, 2013</a>].</li><li>Women may also be taking potentially teratogenic drugs (for example angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, some immunosuppressants, or warfarin), which need to be switched to safer alternatives prior to pregnancy [<a class="bibliography-reference internal-reference" href="../../references/index.html">Bramham and Lightstone, 2012</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Palma-Reis et al, 2013</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Smyth et al, 2013</a>].</li></ul><h5>Not stopping medication unless otherwise directed by a specialist</h5><ul><li>This recommendation is based on what CKS considers to be good clinical practice. It takes into account the adverse outcomes associated with maternal renal disease in pregnancy, and also expert opinion stating that the goal of treatment is to control disease activity [<a class="bibliography-reference internal-reference" href="../../references/index.html">Smyth et al, 2013</a>] and that features of renal disease such as hypertension and proteinuria should be optimised before pregnancy [<a class="bibliography-reference internal-reference" href="../../references/index.html">Wiles et al, 2015</a>].</li></ul><!-- end field 7556cac6-2471-450b-99c5-a0105e825af7 --><!-- end item 2f577f80-1a9a-41fd-8df5-b67018b19c56 --></div></section></section><section aria-labelledby="venous-thromboembolism" class="ChapterBody-module--wrapper--2HCfk "><h3 id="venous-thromboembolism">How do I manage a woman with a history of venous thromboembolism who wishes to become pregnant?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 0b1ab8c0-cf5d-4fbd-a6b7-310c5f75ab0c --><!-- begin field 5d8bf5a6-d79a-4986-ab02-b3b516af73d0 --><ul><li><strong>Seek specialist advice from a clinician with expertise in thrombosis in pregnancy </strong>for women who have a past history of deep vein thrombosis or pulmonary embolism, and for those with an abnormal thrombophilia screen.</li><li><strong>Refer all women receiving warfarin therapy who are planning a pregnancy</strong> to a specialist for advice, as warfarin will need to be stopped or replaced by heparin, depending on the woman's degree of risk of VTE.</li><li>Discuss the standard pre-conception measures (see <a class="topic-reference internal-reference" href="../advice-for-all-women/index.html">Advice for all women</a>).</li></ul><!-- end field 5d8bf5a6-d79a-4986-ab02-b3b516af73d0 --><!-- end item 0b1ab8c0-cf5d-4fbd-a6b7-310c5f75ab0c --></div><section aria-labelledby="basis-for-recommendation-88f" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-88f">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 88fd2268-713c-43ae-8cba-31ea313ebcff --><!-- begin field 4baca31a-411d-4beb-b468-3f25694a3e58 --><h5>Seek specialist advice for women who have a past history of deep vein thrombosis or pulmonary embolism, and for those with an abnormal thrombophilia screen.</h5><ul><li>This recommendation is based on the Royal College of Obstetricians and Gynaecologists (RCOG) guideline <em>Reducing the risk of venous thromboembolism during pregnancy and the puerperium </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">RCOG, 2015</a>].</li><li>Thrombophilia and a history of previous venous thromboembolism (VTE) are both significant risk factors for developing VTE in pregnancy [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCOG, 2015</a>].<strong> </strong>Thrombophilia can have adverse effects on the mother and fetus including pre-eclampsia, placental infarction or abruption, intrauterine growth restriction, and fetal death [<a class="bibliography-reference internal-reference" href="../../references/index.html">Farahi and Zolotor, 2013</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Callegari et al, 2015</a>].<strong> </strong>The RCOG guideline recommends thrombophilia testing for certain groups of women with previous VTE and advises that interpretation of results should be done by clinicians with expertise in the area [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCOG, 2015</a>].</li><li>Pre-pregnancy counselling should be offered to women with a history of VTE to formulate a management plan for thromboprophylaxis in pregnancy as they have an increased risk of recurrence in pregnancy. Management will depend on the underlying cause of VTE and the RCOG recommends collaboration with a haematologist with expertise in thrombosis in pregnancy [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCOG, 2015</a>]. <ul><li>For women with a previous history of recurrent VTE, specialist advice is required regarding dose of low molecular weight heparin in pregnancy as higher doses may be required [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCOG, 2015</a>]. </li></ul></li></ul><h5>Refer all women receiving warfarin therapy who are planning a pregnancy</h5><ul><li>The RCOG recommends counselling of all women taking warfarin or other oral anticoagulants about the associated fetal risks [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCOG, 2015</a>]. <ul><li>Warfarin is teratogenic and should ideally be stopped before conception. This usually involves switching therapy to low-molecular-weight heparin or heparin [<a class="bibliography-reference internal-reference" href="../../references/index.html">Schaefer, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Farahi and Zolotor, 2013</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Callegari et al, 2015</a>].</li></ul></li></ul><!-- end field 4baca31a-411d-4beb-b468-3f25694a3e58 --><!-- end item 88fd2268-713c-43ae-8cba-31ea313ebcff --></div></section></section><section aria-labelledby="rheumatological-conditions" class="ChapterBody-module--wrapper--2HCfk "><h3 id="rheumatological-conditions">How do I manage a woman with a rheumatological condition who wishes to become pregnant?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item ed3ec9c8-71e1-4204-a93b-41ff1a5244ee --><!-- begin field ea99ec84-0861-4a96-acb2-102fe9bc2313 --><ul><li><strong>Refer women with a rheumatological condition</strong> (for example rheumatoid arthritis, systemic lupus erythematosus) who wish to become pregnant to a rheumatologist,<strong> </strong>especially if they are taking nonsteroidal anti-inflammatory drugs (NSAIDs) or disease-modifying anti-rheumatic drugs (DMARDs).</li><li><strong>Ensure the use of effective contraception </strong>whilst taking DMARDs and until a woman planning pregnancy has been reviewed by a specialist. </li><li>Discuss the standard pre-conception measures (see <a class="topic-reference internal-reference" href="../advice-for-all-women/index.html">Advice for all women</a>).</li></ul><!-- end field ea99ec84-0861-4a96-acb2-102fe9bc2313 --><!-- end item ed3ec9c8-71e1-4204-a93b-41ff1a5244ee --></div><section aria-labelledby="basis-for-recommendation-eed" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-eed">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item eed309c6-891d-4992-bc86-3de32a1dc82a --><!-- begin field b4601f69-5033-4e95-9e5d-626ae48121e8 --><h5>Referral to a rheumatologist </h5><ul><li>CKS has based this recommendation on British Society for Rheumatology and British Health Professionals in Rheumatology (BSR/BHPR) guidelines on prescribing drugs in pregnancy and breastfeeding [<a class="bibliography-reference internal-reference" href="../../references/index.html">Flint et al, 2016a</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Flint et al, 2016b</a>], a European League Against Rheumatism consensus on the use of antirheumatic drugs before and during pregnancy and lactation [<a class="bibliography-reference internal-reference" href="../../references/index.html">Gotestam Skorpen et al, 2016</a>] and expert opinion in a review article [<a class="bibliography-reference internal-reference" href="../../references/index.html">Soh and Nelson-Piercy, 2015</a>]. Referral enables discussion of:<ul><li>Medication — may be reviewed to weigh the risk of drug treatment for the fetus against the risk to the mother and fetus of untreated disease. Some drugs used for rheumatic conditions should not be used when trying to conceive or during pregnancy due to teratogenic risks or lack of safety data, and may need to be stopped in advance of conception (examples include methotrexate, cyclophosphamide, and mycophenolate mofetil) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Soh and Nelson-Piercy, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Flint et al, 2016a</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Flint et al, 2016b</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Gotestam Skorpen et al, 2016</a>].</li><li>Potential risks in pregnancy associated with the underlying rheumatic disease — women with rheumatic diseases are at increased risk of adverse pregnancy outcomes including pre-eclampsia, preterm delivery, and fetal growth restriction. They may also have co-morbidities (for example renal disease, steroid-induced diabetes) that need to be considered [<a class="bibliography-reference internal-reference" href="../../references/index.html">Soh and Nelson-Piercy, 2015</a>].</li></ul></li></ul><h5>Use of effective contraception</h5><ul><li>Because of the teratogenic and fetotoxic effects of some DMARDs [<a class="bibliography-reference internal-reference" href="../../references/index.html">Soh and Nelson-Piercy, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Flint et al, 2016a</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Gotestam Skorpen et al, 2016</a>], CKS recommends that women should be advised to continue using effective contraception until their medication has been reviewed, and in some cases for several months after stopping medication.</li></ul><!-- end field b4601f69-5033-4e95-9e5d-626ae48121e8 --><!-- end item eed309c6-891d-4992-bc86-3de32a1dc82a --></div></section></section><section aria-labelledby="inflammatory-bowel-disease" class="ChapterBody-module--wrapper--2HCfk "><h3 id="inflammatory-bowel-disease">How should I manage a woman with inflammatory bowel disease who wishes to become pregnant?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 2ec0eb07-1a3e-4953-8354-a7b400e235dc --><!-- begin field 7fb8915c-e773-4a6e-8a01-a7b400e23cdb --><ul><li><strong>Reassure the woman</strong> that fertility rates in women with inflammatory bowel disease (IBD) are generally similar to the rest of the population.</li><li><strong>Refer women with inflammatory bowel disease who wish to become pregnant</strong> to a gastroenterologist.<ul><li>Advise the woman to continue using effective contraception until a full assessment by the specialist has taken place. </li><li>Advise the woman not to stop taking her medication unless otherwise directed by the specialist.</li></ul></li><li>Offer written patient information, such as that available from Crohn's and Colitis UK on <a href="https://www.crohnsandcolitis.org.uk/about-inflammatory-bowel-disease/publications/fertility-ibd" data-hyperlink-id="d105b230-a2ba-42b0-bcee-a93100ad9a38">Fertility and IBD</a> and <a href="https://www.crohnsandcolitis.org.uk/about-inflammatory-bowel-disease/publications/pregnancy-ibd" data-hyperlink-id="93df7608-c31d-4861-a99a-a93100ad9ac1">Pregnancy and IBD</a>. </li><li>Discuss the standard pre-conception measures (see <a class="topic-reference internal-reference" href="../advice-for-all-women/index.html">Advice for all women</a>).<ul><li>Ensure the woman is taking an appropriate dose of folic acid.</li></ul></li></ul><!-- end field 7fb8915c-e773-4a6e-8a01-a7b400e23cdb --><!-- end item 2ec0eb07-1a3e-4953-8354-a7b400e235dc --></div><section aria-labelledby="basis-for-recommendation-6c7" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-6c7">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 6c7a02e3-02a8-4bb3-81ba-a7b400e23d9f --><!-- begin field cf114b86-fa62-4aa3-9c3b-a7b400e23da4 --><h5>Reassurance</h5><ul><li>This recommendation is based on the Faculty of Sexual and Reproductive Healthcare (FSRH) guideline on <em>Sexual and reproductive health for individuals with inflammatory bowel disease </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2016</a>]<em>.</em><strong> </strong>However, there is some evidence to suggest that in women with active Crohn's disease or adhesions from surgery, fertility may be decreased [<a class="bibliography-reference internal-reference" href="../../references/index.html">Mowat et al, 2011</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">van der Woude et al, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2016</a>].</li></ul><h5>Referral </h5><ul><li>This recommendation is based on the FSRH guideline on <em>Sexual and reproductive health for individuals with inflammatory bowel disease</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2016</a>]<strong> </strong>and the British Society of Gastroenterology publication <em>Guidelines for the management of inflammatory bowel disease in adults</em><strong><em> </em></strong>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Mowat et al, 2011</a>].<ul><li>Referral for pre-pregnancy counselling ensures optimal management of IBD before the woman becomes pregnant because the best time to conceive is when IBD is controlled and the woman is well nourished [<a class="bibliography-reference internal-reference" href="../../references/index.html">Mowat et al, 2011</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">van der Woude et al, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2016</a>]. Women with active disease at conception are more likely to experience active disease when they are pregnant [<a class="bibliography-reference internal-reference" href="../../references/index.html">van der Woude et al, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2016</a>].</li><li>Specialist involvement is beneficial because although most pregnancies in women with controlled IBD are uncomplicated [<a class="bibliography-reference internal-reference" href="../../references/index.html">Kanis and van der Woude, 2016</a>], women with active IBD are at increased risk of spontaneous abortion, preterm labour, and small for gestational age and low birthweight babies<strong> </strong>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Mowat et al, 2011</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">van der Woude et al, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Kanis and van der Woude, 2016</a>] and pregnancy may affect the course of IBD [<a class="bibliography-reference internal-reference" href="../../references/index.html">van der Woude et al, 2015</a>]. </li><li>Medication review prior to pregnancy is important because of the need for some drugs for IBD to be stopped before conception because of the risks of congenital abnormalities [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2016</a>].</li></ul></li></ul><h5>Continuing effective contraception until after a full specialist assessment</h5><ul><li>CKS has made this recommendation because although most medications for IBD are not related to adverse outcomes in pregnancy [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lanzon-Miller, 2012</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Vermeire et al, 2012</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Kanis and van der Woude, 2016</a>], some drugs used for its treatment can be harmful to the fetus and effective contraceptive use is necessary for some time after treatment has stopped (for example methotrexate, mercaptopurine, mycophenolate mofetil, TNF-alpha inhibitors) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Kubota-Sjogren et al, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">BNF 73, 2017</a>].</li></ul><h5>Advising not to stop medication unless otherwise directed by the specialist</h5><ul><li>The FSRH guideline on <em>Sexual and reproductive health for individuals with inflammatory bowel disease</em> advises encouraging women to continue with medication [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2016</a>].<strong> </strong>Expert opinion in a review article comments on the possibility of relapse if maintenance treatment is stopped and recommends counselling women wanting to conceive regarding this to reduce the risk of disease flares in pregnancy which are associated with adverse maternal and fetal outcomes [<a class="bibliography-reference internal-reference" href="../../references/index.html">van der Woude et al, 2015</a>].<strong> </strong>Many adverse outcomes occur in relation to disease activity rather than the drugs taken to control IBD and the benefits of controlled disease outweigh the fetal risks of medication [<a class="bibliography-reference internal-reference" href="../../references/index.html">Mowat et al, 2011</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Lanzon-Miller, 2012</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Kubota-Sjogren et al, 2014</a>].</li></ul><h5>Dose of folic acid</h5><ul><li>FSRH guidelines recommend that the standard 400 microgram daily dose of folic acid is usually suitable for women with IBD, but some (for example women on sulfasalazine, or those who have malabsorption after surgery to resect the small bowel) may need a higher dose [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2016</a>]. This is also supported by expert opinion in a review article [<a class="bibliography-reference internal-reference" href="../../references/index.html">Kubota-Sjogren et al, 2014</a>]. The British National Formulary considers the children of pregnant women with malabsorption states to be at high risk of neural tube defects and recommends a folic acid dose of 5 mg daily, to be taken before conception and until week 12 of pregnancy [<a class="bibliography-reference internal-reference" href="../../references/index.html">BNF 73, 2017</a>].</li></ul><!-- end field cf114b86-fa62-4aa3-9c3b-a7b400e23da4 --><!-- end item 6c7a02e3-02a8-4bb3-81ba-a7b400e23d9f --></div></section></section><section aria-labelledby="haemoglobinopathies" class="ChapterBody-module--wrapper--2HCfk "><h3 id="haemoglobinopathies">How should I manage a woman with sickle-cell disease or thalassaemia who wishes to become pregnant?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item ef22ebe0-ff54-43a3-bb4c-a7bc008a3ed3 --><!-- begin field 7314f653-41af-441b-97ca-a7bc008a4073 --><ul><li><strong>Refer all women with sickle cell disease or thalassaemia to a haematologist</strong> for assessment and monitoring.</li><li>Women who are sickle cell or thalassaemia carriers (sickle cell or thalassaemia trait) usually have no related health issues.  <ul><li>Advise women who carry the sickle cell (S) gene that they may have problems in situations where there are changes in levels of available oxygen. </li><li>Advise women who are beta-thalassaemia carriers that the size of their red blood cells and levels of haemoglobin can cause confusion with iron deficiency anaemia, so testing for iron deficiency is important before taking iron supplements.</li><li>Advise that if their partner is also a carrier of an unusual haemoglobin gene, their baby may inherit a haemoglobin condition, therefore testing is advised.<strong> </strong>For more information, see the <a class="topic-reference internal-reference" href="../genetic-risk-assessment/index.html">Scenario: Genetic risk assessment</a>. </li></ul></li><li>Ensure women with sickle cell disease, thalassaemia, or thalassaemia trait receive folic acid 5 mg daily throughout pregnancy. </li><li>Discuss the standard pre-conception measures (see <a class="topic-reference internal-reference" href="../advice-for-all-women/index.html">Advice for all women</a>).</li></ul><!-- end field 7314f653-41af-441b-97ca-a7bc008a4073 --><!-- end item ef22ebe0-ff54-43a3-bb4c-a7bc008a3ed3 --></div><section aria-labelledby="basis-for-recommendation-e94" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-e94">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item e9408e4f-76f9-4739-8b80-a7bc008a407e --><!-- begin field 9eb4fe4b-cda9-4e16-9fcd-a7bc008a407e --><h5>Referral of women with sickle cell disease for assessment and monitoring</h5><ul><li>This recommendation is based on the Royal College of Obstetricians and Gynaecologists guideline <em>Management of Sickle cell disease in pregnancy </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">RCOG, 2011a</a>]<strong> </strong>and expert opinion in a review article that concludes that despite the risk of complications for women with haemoglobinopathies, successful pregnancies are possible with close monitoring by experienced haematologists and obstetricians [<a class="bibliography-reference internal-reference" href="../../references/index.html">Naik and Lanzkron, 2012</a>].<ul><li>Expert opinion in the RCOG guideline recommends pre-conception counselling by a specialist to enable the woman to be informed about the effects of sickle cell disease on pregnancy and vice versa. This also allows formulation of a management plan including [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCOG, 2011a</a>]:<ul><li>Information on factors increasing the risk of sickle cell crises, such as nausea and vomiting in pregnancy, cold, overexertion, and stress.</li><li>Explanation of increased risks of worsening anaemia, crises and acute chest syndrome, infections (especially of the urinary system), growth restriction of the baby, fetal distress, induction of labour and caesarean section.</li><li>Discussion of the chance of the woman's baby having sickle cell disease.</li><li>Assessment of chronic disease complications such as pulmonary hypertension, hypertension, sickle nephropathy, proliferative retinopathy, and iron overload.</li><li>Review of antibiotic prophylaxis and vaccination status.</li><li>Review of medication — some drugs used for sickle cell disease and its complications, such as hydroxycarbamide, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers are not safe to use in pregnancy and need to be stopped before a woman conceives.</li></ul></li><li>Complications affecting the mother and fetus associated with sickle cell disease include an increased risk of acute painful crises during pregnancy, pre-eclampsia, fetal growth restriction, perinatal mortality, premature labour, thromboembolic events, and antepartum haemorrhage [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCOG, 2011a</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Naik and Lanzkron, 2012</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">NHLBI, 2014</a>].</li></ul></li></ul><h5>Referral of women with thalassaemia for assessment and monitoring</h5><ul><li>This recommendation is based on a Royal College of Obstetricians and Gynaecologists (RCOG) guideline on <em>Management of beta thalassaemia in pregnancy</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCOG, 2014</a>]<strong> </strong>and expert opinion in a review article that concludes that despite the risk of complications for women with haemoglobinopathies, successful pregnancies are possible with close monitoring by experienced haematologists and obstetricians [<a class="bibliography-reference internal-reference" href="../../references/index.html">Naik and Lanzkron, 2012</a>]<ul><li>Risks to the mother and baby are increased in pregnancies affected by beta thalassaemia. Data are limited due to the geographical distribution of many people with the disease and the increased risk of hypogonadotrophic hypogonadism (related to transfusion iron overload) affecting fertility [<a class="bibliography-reference internal-reference" href="../../references/index.html">Naik and Lanzkron, 2012</a>]. Adverse outcomes include worsening of anaemia; maternal cardiomyopathy due to iron overload; the risk of a pregnant woman developing endocrinopathies such as diabetes mellitus, hypothyroidism and hypoparathyroidism; and fetal growth restriction [<a class="bibliography-reference internal-reference" href="../../references/index.html">Naik and Lanzkron, 2012</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">RCOG, 2014</a>].</li><li>The RCOG guideline states that women with beta thalassaemia are ideally looked after by a multidisciplinary team including a specialist obstetrician and haematologist which should provide pre-conception counselling. This allows the woman to receive information about the impact of thalassaemia on her pregnancy and how pregnancy affects thalassaemia and enables the team to plan management. Iron chelation therapy may be required prior to pregnancy to control iron overload so referral well in advance of pregnancy is important [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCOG, 2014</a>].</li></ul></li><li>Women with haemoglobin H disease (three alpha globin genes are absent) may experience varying severity of anaemia, jaundice, and hepatosplenomegaly [<a class="bibliography-reference internal-reference" href="../../references/index.html">Clark et al, 2012</a>]. In pregnancy, severe anaemia may occur, and haemolytic crisis can result in oxidative stress or infection [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lao, 2017</a>], therefore CKS recommends referral for women with haemoglobin H disease planning a pregnancy.</li><li>Inheritance of one unusual haemoglobin gene from one parent (sickle cell or thalassaemia trait) does not usually cause health issues [<a class="bibliography-reference internal-reference" href="../../references/index.html">PHE, 2013b</a>]<strong> </strong>and limited evidence suggests women with thalassaemia trait have pregnancy outcomes similar to the general population [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lao, 2017</a>]. The recommendations on advice to give women with sickle cell or thalassaemia trait are based on Public Health England's (PHE) <em>Sickle cell and thalassaemia: programme overview </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">PHE, 2013b</a>], and also information for adult haemoglobinopathy carriers from PHE for sickle cell carriers and beta thalassaemia carriers [<a class="bibliography-reference internal-reference" href="../../references/index.html">PHE, 2016f</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">PHE, 2016g</a>].<ul><li>Women who have one or two gene deletion alpha thalassaemia are usually asymptomatic with normal pregnancy outcomes, although they may have a mild hypochromic microcytic anaemia [<a class="bibliography-reference internal-reference" href="../../references/index.html">Perry and Lowndes, 2010</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Clark et al, 2012</a>].</li></ul></li></ul><h5>Folic acid</h5><ul><li>For women with sickle cell disease, the RCOG guideline <em>Management of Sickle cell disease in pregnancy</em> recommends that folic acid should be given at a dose of 5 mg daily pre-conceptually and during pregnancy. This is to reduce the risk of neural tube defects and address the increased need for folate during pregnancy. The haemolytic anaemia of sickle cell disease increases a woman's risk of folate deficiency [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCOG, 2011a</a>].</li><li>For women with thalassaemia, the RCOG guideline <em>Management of beta thalassaemia in pregnancy</em> recommends a dose of 5 mg folic acid daily, to start 3 months before conception. This dose reduces the risk of neural tube defects as the demand for folic acid is higher in women with thalassaemia [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCOG, 2014</a>]. Expert opinion in a review article also recommends folic acid supplementation before and during pregnancy for women with thalassaemia [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lao, 2017</a>]. Haemolysis is a predominant feature of haemoglobin H disease (three absent alpha globin genes) and is exacerbated by pregnancy, so experts recommend prophylactic folic acid 5 mg daily [<a class="bibliography-reference internal-reference" href="../../references/index.html">Clark et al, 2012</a>]. </li><li>Women with thalassemia trait are anaemic because erythropoiesis is ineffective. The increased turnover in the bone marrow results in folate depletion. Expert advice in a textbook suggests that these women will probably benefit from taking 5 mg of folic acid daily throughout pregnancy [<a class="bibliography-reference internal-reference" href="../../references/index.html">Strong and Rutherford, 2011</a>].</li></ul><!-- end field 9eb4fe4b-cda9-4e16-9fcd-a7bc008a407e --><!-- end item e9408e4f-76f9-4739-8b80-a7bc008a407e --></div></section></section></section></div></div></div><div class="BackToTop-module--wrapper--2Z0EU"><nav aria-labelledby="back-to-top-link" class="BackToTop-module--nav--1DPZ6"><a class="BackToTop-module--anchor--1Nia6" id="back-to-top-link" href="index.html#content-start"><div class="container"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="icon" aria-hidden="true" focusable="false"><path d="M478.152 338.576c0 10.091-3.525 18.661-10.576 25.712l-21.424 21.424c-7.243 7.243-15.909 10.864-26 10.864-10.283 0-18.853-3.621-25.712-10.864L255.576 247.136 116.712 385.712c-6.859 7.243-15.429 10.864-25.712 10.864s-18.853-3.621-25.712-10.864l-21.424-21.424C36.621 357.429 33 348.859 33 338.576c0-10.091 3.621-18.757 10.864-26l186-186c7.051-7.051 15.621-10.576 25.712-10.576 9.909 0 18.576 3.525 26 10.576l185.712 186c7.243 7.243 10.864 15.909 10.864 26z" fill="currentColor"></path></svg> Back to top</div></a></nav></div></main><footer class="Footer-module--footer--2QrGZ"><div class="Footer-module--container--1iuoB"><a href="https://www.nice.org.uk/" class="Footer-module--logo--3DGKv" aria-label="Go to NICE home page"></a><nav class="Services-module--wrapper--2qOoE" aria-label="Our services"><ul class="Services-module--list--3SZQu"><li><a href="https://pathways.nice.org.uk/" class="Services-module--link--2y_1q">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Services-module--link--2y_1q">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Services-module--link--2y_1q">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Services-module--link--2y_1q">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary">BNF<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Services-module--link--2y_1q"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Services-module--visuallyHidden--t9mfm">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">Clinical Knowledge Summaries</span></a></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Services-module--link--2y_1q">Journals and databases</a></li></ul></nav><nav class="Pages-module--wrapper--30REl"><ul class="Pages-module--list--vvSk4"><li><a href="https://www.nice.org.uk/about">About NICE</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/into-practice">Into practice</a></li><li><a href="https://www.nice.org.uk/get-involved">Get involved with NICE</a></li><li><a href="https://www.nice.org.uk/get-involved/jobs">Jobs</a></li><li><a href="https://www.nice.org.uk/news">News</a></li><li><a href="https://www.nice.org.uk/news/nice-newsletters-and-alerts">Newsletters and alerts</a></li><li><a href="https://www.nice.org.uk/get-involved/contact-us">Contact us</a></li><li><a href="https://www.nice.org.uk/leave-feedback">Leave feedback</a></li><li><a href="https://www.nice.org.uk/re-using-our-content">Reusing our content</a></li><li><a href="https://www.nice.org.uk/re-using-our-content/uk-open-content-licence">NICE UK Open Content Licence</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/nice-syndication-api">Syndicate our content</a></li></ul></nav><div class="Social-module--wrapper--2nKsd"><ul class="Social-module--list--E5R5J" aria-label="NICE on social media"><li><a href="https://en-gb.facebook.com/NationalInstituteforHealthandCareExcellence/">Facebook</a></li><li><a href="https://twitter.com/NICEcomms">Twitter</a></li><li><a href="https://www.youtube.com/user/NICEmedia">YouTube</a></li><li><a href="https://www.instagram.com/nicecomms/">Instagram</a></li><li><a href="https://www.linkedin.com/company/national-institute-for-health-and-clinical-excellence">LinkedIn</a></li></ul></div></div><div class="Legal-module--wrapper--3AYMO"><div class="Legal-module--container--3TTBh"><nav class="Legal-module--menu--1e1Iy" aria-label="Legal menu"><ul><li><a href="https://www.nice.org.uk/accessibility">Accessibility</a></li><li><a href="https://www.nice.org.uk/freedom-of-information">Freedom of information</a></li><li><a href="https://www.nice.org.uk/glossary">Glossary</a></li><li><a href="https://www.nice.org.uk/terms-and-conditions">Terms and conditions</a></li><li><a href="https://www.nice.org.uk/privacy-notice">Privacy notice</a></li><li><a href="https://www.nice.org.uk/cookies">Cookies</a></li></ul></nav><p class="Legal-module--copyright--34nsI">©<!-- --> <abbr title="National Institute for Health and Care Excellence">NICE</abbr> <!-- -->2021<!-- -->. All rights reserved. Subject to<!-- --> <a href="https://www.nice.org.uk/terms-and-conditions#notice-of-rights">Notice of rights</a>.</p></div></div></footer></div><div id="gatsby-announcer" style="position:absolute;top:0;width:1px;height:1px;padding:0;overflow:hidden;clip:rect(0, 0, 0, 0);white-space:nowrap;border:0" aria-live="assertive" aria-atomic="true"></div></div><script id="gatsby-script-loader">/*<![CDATA[*/window.pagePath="/topics/pre-conception-advice-management/management/chronic-medical-conditions/";/*]]>*/</script><script id="gatsby-chunk-mapping">/*<![CDATA[*/window.___chunkMapping={"polyfill":["/polyfill-2cb897c2a056d28c9332.js"],"app":["/app-53a71c38b210970893c4.js"],"component---cache-caches-gatsby-plugin-offline-app-shell-js":["/component---cache-caches-gatsby-plugin-offline-app-shell-js-258fa972005c75a2a109.js"],"component---src-pages-404-tsx":["/component---src-pages-404-tsx.4b20f8dadfa146d0f95d.css","/component---src-pages-404-tsx-db046304e34e9a4e982b.js"],"component---src-pages-about-development-tsx":["/component---src-pages-about-development-tsx.4c5b5dd941fb0f6fd929.css","/component---src-pages-about-development-tsx-a805dcaba6372bd3fd34.js"],"component---src-pages-about-index-tsx":["/component---src-pages-about-index-tsx.a9a4b7f951b698486005.css","/component---src-pages-about-index-tsx-d5e998d3f688352286e1.js"],"component---src-pages-index-tsx":["/component---src-pages-index-tsx.49dafffcf9ae0c5f0d9f.css","/component---src-pages-index-tsx-6cc2ff789de11ec327f6.js"],"component---src-pages-search-tsx":["/component---src-pages-search-tsx.f915457cd8b05c27e895.css","/component---src-pages-search-tsx-a51f99760cb0d47808e2.js"],"component---src-pages-specialities-tsx":["/component---src-pages-specialities-tsx.fc62cf637c7ba1e609e7.css","/component---src-pages-specialities-tsx-90b8d3e5a5a3bff52a17.js"],"component---src-pages-topics-tsx":["/component---src-pages-topics-tsx.dfa0c1027e3cbeb11bdc.css","/component---src-pages-topics-tsx-960f75c13acbee11c017.js"],"component---src-pages-whats-new-tsx":["/component---src-pages-whats-new-tsx.7f7660f22ce5e07ac85a.css","/component---src-pages-whats-new-tsx-f78b713a66b42005fd9f.js"],"component---src-templates-chapter-level-1-chapter-level-1-tsx":["/component---src-templates-chapter-level-1-chapter-level-1-tsx.1a16ce552cccd7e50c41.css","/component---src-templates-chapter-level-1-chapter-level-1-tsx-0a03778bb80ba711929e.js"],"component---src-templates-chapter-level-2-chapter-level-2-tsx":["/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css","/component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"],"component---src-templates-speciality-speciality-tsx":["/component---src-templates-speciality-speciality-tsx.fc62cf637c7ba1e609e7.css","/component---src-templates-speciality-speciality-tsx-3357943d471e489a1b5f.js"],"component---src-templates-topic-topic-tsx":["/component---src-templates-topic-topic-tsx.afc04214919e241c3c2e.css","/component---src-templates-topic-topic-tsx-f17fe03d0b9a54a96aea.js"]};/*]]>*/</script><script src="../../../../polyfill-2cb897c2a056d28c9332.js" nomodule=""></script><script src="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js" async=""></script><script src="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js" async=""></script><script src="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js" async=""></script><script src="../../../../app-53a71c38b210970893c4.js" async=""></script><script src="../../../../framework-34da02e39e1f104d9937.js" async=""></script><script src="../../../../webpack-runtime-28c424ef71f39faedaf0.js" async=""></script></body></html>